WO2006020060A2 - Iap binding compounds - Google Patents
Iap binding compounds Download PDFInfo
- Publication number
- WO2006020060A2 WO2006020060A2 PCT/US2005/025208 US2005025208W WO2006020060A2 WO 2006020060 A2 WO2006020060 A2 WO 2006020060A2 US 2005025208 W US2005025208 W US 2005025208W WO 2006020060 A2 WO2006020060 A2 WO 2006020060A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- groups
- ofr
- optionally
- alkyl
- Prior art date
Links
- 0 Cc1c(*)c(*)c(*)c(*)c1* Chemical compound Cc1c(*)c(*)c(*)c(*)c1* 0.000 description 12
- KQXJVGJKCCKERE-JSGCOSHPSA-N CC(C)(C)OC(N(C1)[C@H](CO)C[C@@H]1Oc1ccccc1)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](CO)C[C@@H]1Oc1ccccc1)=O KQXJVGJKCCKERE-JSGCOSHPSA-N 0.000 description 1
- VNOHFQDJIWTMOL-PXNSSMCTSA-N CC(C)(C)OC(N(C1)[C@H](COc2ccccc2)C[C@@H]1Oc1ccccc1)=O Chemical compound CC(C)(C)OC(N(C1)[C@H](COc2ccccc2)C[C@@H]1Oc1ccccc1)=O VNOHFQDJIWTMOL-PXNSSMCTSA-N 0.000 description 1
- VXFSVOQEYAZSPH-LTGDSAQFSA-N CC(C)C(C(N(C1)[C@H](COc2ccccc2)C[C@@H]1Oc1ccccc1)=O)N Chemical compound CC(C)C(C(N(C1)[C@H](COc2ccccc2)C[C@@H]1Oc1ccccc1)=O)N VXFSVOQEYAZSPH-LTGDSAQFSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Definitions
- Apoptosis programmed cell death, plays a central role in the development and homeostasis of all multi-cellular organisms. Alterations in apoptotic pathways have been implicated in many types of human pathologies, including developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders.
- Apoptosis is executed primarily by activated caspases, a family of cysteine proteases with aspartate specificity in their substrates.
- Caspases are produced in cells as catalytically inactive zymogens and must be proteolytically processed to become active proteases during apoptosis. hi normal surviving cells that have not received an apoptotic stimulus, most caspases remain inactive. Even if some caspases are aberrantly activated, their proteolytic activity can be fully inhibited by a family of evolutionarily conserved proteins called IAPs (inhibitors of apoptosis proteins) (Deveraux & Reed, Genes Dev. 13: 239-252,1999).
- IAPs inhibitors of apoptosis proteins
- Each of the IAPs contains 1-3 copies of the so-called BIR (baculoviral IAP repeat) domain and directly interacts with and inhibits the enzymatic activity of mature caspases.
- BIR baculoviral IAP repeat
- Several distinct mammalian IAPs including XIAP, survivin, and LIVIN/ML-IAP, (Kasof and Gomes, J. Biol. Chem. 276: 3238-3246,2001; Vucic et al. Curr. Biol. 10: 1359-1366,2000; Ashhab et al. FEBS Lett. 495: 56-60,2001), have been identified and they exhibit anti-apoptotic activity in cell culture (Deveraux & Reed, 1999, supra). As IAPs are expressed in most cancer cells, they may directly contribute to tumor progression and subsequent resistance to drug treatment.
- Smac second mitochondria-derived activator of caspases
- DIABLO direct IAP binding protein with low pi
- Verhagen et al. Cell 102: 43- 53,2000 a mitochondrial protein named Smac/DIABLO, synthesized in the cytoplasm, is targeted to the inter-membrane space of mitochondria. Upon apoptotic stimuli, Smac is released from mitochondria back into the cytosol, together with cytochrome c.
- Smac eliminates the inhibitory effect of multiple IAPs.
- Smac interacts with all IAPs that have been examined to date, including XIAP, c-IAPl, c- IAP2, ML-IAP, and survivin.
- Smac appears to be a regulator of apoptosis in mammals.
- overexpressed IAPs can function to bind Smac and prevent it from binding to XIAP and releasing caspases (Vucic et. al., Biochem. J. 385(Pt 1):11-20, 2005).
- Smac is synthesized as a precursor molecule of 239 amino acids; the N- terminal 55 residues serve as the mitochondria targeting sequence that is removed after import.
- the mature form of Smac contains 184 amino acids and behaves as an oligomer in solution.
- Smac and various fragments of it have been proposed for use as targets for identification of therapeutic agents.
- the biological activity of Smac is believed to be related to binding of its N-terminal four residues to a featured surface groove in a portion of XIAP referred to as the BIR3 domain. This binding prevents XIAP from exerting its apoptosis-suppressing function in the cell.
- the N- terminal tetrapeptides from IAP binding proteins of the Drosophila pro-apoptotic proteins Hid, Grim and Reaper are believed to function in the same manner.
- the BIR domain of an IAP is contacted with the labeled LAP peptide or peptidomimetic to form a complex, and the complex is exposed to a compound to be tested for BIR binding. Displacement of the labeled IAP peptide or peptidomimetic from the complex, if any, by the test compound, is measured.
- Disadvantages in the use of peptides for in vivo administration as diagnostic or therapeutic agents may include their short half-life due to proteolytic degradation of the peptide in the body, low absorption through intestinal walls, potential immunogenic reactions, as well as expense involved in peptide synthesis. It would be beneficial to prepare non-peptidic IAP binding compounds that have comparable biological activity of bioactive peptides, but possess improved pharmacological properties and are easier or less expensive to synthesize.
- IAP-binding compounds which may be used to promote apoptosis, while also having the improved properties associated with non- peptide compounds.
- Such compounds can be used as diagnostic and therapeutic agents in the treatment of apoptosis related conditions.
- An embodiment of the present invention is a compound, or composition comprising a compound, of the general formula (2):
- a 1 and A 2 are independently hydrogen, alkyl, aryl, or alkylaryl group, R la is H or a methyl group; R ⁇ is an alkyl or aryl group; X 1 is -O-,-S-,-CH 2 -, or-NH- group, and J is -CH-, or -N- group, provided that when J is-N-, X 1 is -CH 2 -, or -NH- group; Y is H, or an alkyl group ; Z is -OH, aryloxy, alkoxy, benzyloxy, benzyloxy, amino, arylamino, alkylamino, benzylamino group ; R 2 is a detectable label or is :
- M is alkylene, alkenylene, alkynlene, heteroalkylene, heteroalkenylene, or heteroalkynlene group
- G is selected from a bond, -O-; -N(R 2d )- where R 2( j is H, alkyl, cycloalkyl, or aryl; or -S(O) m - where m is 0, 1, or 2; and R 10 is cycloalkyl, aryl, heterocycloalkyl, heterocycloalkenyl, or heteroaryl; n is independently the integer 0, 1, 2, 3, 4, or 5.
- Another embodiment of the present invention is a compound, or composition including a compound, of the general formula (3):
- a 1 is H, lower alkyl, or optionally-substituted lower alkyl group
- R la and R ⁇ are separately H, lower alkyl, optionally-substituted lower alkyl, lower alkylene, optionally substituted lower alkylene group; or A 1 together with either R 1 a or R 11 , form an optionally substituted heterocycloalkyl group of 3 to 6 atoms
- Y is H, an alkyl group, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, aryl, heteroaryl, arylalkyl, optionally-substituted versions of these groups, hydroxy substituted versions of these groups, or Y together with Z, M, G, or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z, M, G, or R 10 ; Z is H, alkyl, hydroxy, amino, alkylamin
- X 2 is a heteroatom and independently groups Rj 1 , R' ⁇ , R 12 , any OfR 13-17 , or any OfR 14-17 is H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently Rn, R' ⁇ , R 12 , any OfR 13-17 , or any OfR 14-17 is H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; or independently R 11 , R' ⁇ , R 12 , any OfR 13-17 , or any OfRi 4-17
- Another embodiment is compound, or a composition comprising a compound, of the general formula (5)
- a 1 is H, or lower alkyl
- R la is H
- R ⁇ is lower alkyl group
- Y is an alkyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, hydroxy substituted versions of these groups
- Z la and Zi b are independently an H, hydroxy, alkoxy, aryloxy, or heteroaryloxy group
- M is an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms
- G is a bond, a heteroatom, or -NCOR 18 - and R 18 is lower alkyl, optionally-substituted lower alkyl group
- R 10 is anyone of structures (4a), (4b), (4c) or (4d):
- Rn, R' ⁇ , R 12 , any of R 13-17 , or any of R 14-17 are H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R' 11; R 12 , any OfR 13-17 , or any OfR 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R' ⁇ , R 12 , any OfR 13-17 , or any OfR 14-17 are acy
- the present invention is compound, or a composition comprising a compound, of the general formula (5)
- a 1 is H, or lower alkyl
- R la is H
- R ⁇ is lower alkyl group
- Y is an alkyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, hydroxy substituted versions of these groups
- Z la and Zw 3 are independently an H, hydroxy, alkoxy, aryloxy, or heteroaryloxy group
- M is an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms
- G is a bond, a heteroatom, or -NCOR 18 - and R 18 is lower alkyl, optionally-substituted lower alkyl group
- R 1O is anyone of structures (4a), (4b), (4c) or
- R 11 , R' 11; R 12 , any OfR 13-17 , or any OfR 14-17 are H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently Rn, R' ⁇ , Ri 2> any OfR 13-17 , or any of R 14- I 7 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R' ⁇ , R 12 , any of R 13-17 , or any OfR 14-17 are H, halogen, alkyl, alken
- IAP binding molecules can bind to a variety of IAP's (Inhibitor of Apoptosis Proteins). These molecules may be monomers or dimers and may also include a detectable label or therapeutic moiety and can be formulated as pharmaceutical or diagnostic compositions containing these molecules. Methods for using these compounds as therapeutic and diagnostic agents are also described.
- the IAP binding molecules of the present invention can permeate, be transfected, or otherwise be actively or passively transported into cells and can be used to displace IAPs from other proteins like caspases or Smac in cells. At least a portion of the LAP binding-cargo molecule binds to a BIR domain of an LAP.
- the IAP binding cargo molecule may provide a therapeutic effect for a cell proliferation disorder and can include additional therapeutic, diagnostic, or other substituents in the molecule.
- Embodiments of the LAP binding molecules include derivatives of pyrrolidine that bind to a BLR domain of an LAP.
- Embodiments of the present invention include LAP binding cargo molecules and pharmaceutically acceptable salts thereof having the general structure of formula (2):
- a 1 and A 2 can independently be hydrogen, alkyl, aryl, or alkylaryl group, R la can be H or a methyl group;
- R 1I3 may be an alkyl or aryl group, in some embodiments Rn, is methyl, ethyl, n-propyl, isopropyl, or ethenyl group;
- X 1 can be -O-,-S-,-CH 2 -, or-NH- group, and J can be -CH-, or -N- group, provided that when J is-N-, X 1 is -CH 2 -, or an -NH- group;
- Y can be H, or an alkyl group;
- Z can be H, -OH, aryloxy, alkoxy, benzyloxy, amino, arylamino, alkylamino, benzylamino group, in some embodiments Z is -OH, aryloxy, alkoxy, benzyloxy,
- R 2a can be an aryl, cycloalkyl, optionally substituted aralkyl, or cycloalkylalkyl group
- R 2b can be H or alkyl group
- R 2c can be aryl, cycloalkyl, optionally substituted aralkyl, or cycloalkylalkyl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or cycloalkylaryl group.
- R 2c is tetrahydronaphthyl or substituted tetrahydronapthyl group, most preferably R 2c is
- M can be alkylene, alkenylene, alkynlene, heteroalkylene, heteroalkenylene, heteroalkynlene group, in some embodiments M is:
- G can be selected from a bond (i.e., G is absent), -O-; - N(R 2d )- where R 2d can be H, alkyl, cycloalkyl, or aryl; or -S(O) m - where m is 0, 1, or 2;
- R 10 can be cycloalkyl, aryl, heterocycloalkyl, heterocycloalkenyl, or heteroaryl; in some embodiments R 10 is:
- a 1 is H, A 2 is methyl, Ri a is H, Rn 3 is methyl, X 1 is -NH-, J is -CH-, Y is t-butyl, Z is (- OC 6 Hs) and (3*) has an (S) configuration, (4*) has an (S) configuration, (5*) has an (S) or (R) configuration, (6*) has an (S) or (R) configuration, and (7*) has an (R) configuration.
- Some embodiments of compounds of structure (2) have a K d as determined by the methods described, for example, in Example 1 of less than 100 micromolar, preferably less than 1 micromolar, and even more preferably less than 0.1 micromolar.
- LAP binding compounds or LAP binding cargo molecules of structure (2) where A 2 is H, X 1 is -NH-, J is -CH-, and n is 0 for R 2 , can be depicted by structure (3):
- a 1 can be H, lower alkyl, or optionally-substituted lower alkyl group;
- R la and R ⁇ can separately be H, lower alkyl, optionally substituted lower alkyl, lower alkylene, optionally substituted lower alkylene group; or
- a 1 together with either R 1 a or R ⁇ can form an optionally substituted heterocycloalkyl group of 3 to 6 atoms;
- Y can be H, an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, aryl, heteroalkynyl, heteroaryl, or arylalkyl group; optionally-substituted versions of the aforementioned groups; hydroxy substituted versions of the aforementioned groups; or Y together with Z, M, G, or R 10 forms an optionally substituted carbocyclic ring, or an optionally substituted heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z, M, G, or R 10 ; preferably Y is linked to M, G, or R 10 by any number of atoms up to about 20 atoms.
- Z can be H, alkyl, hydroxy, amino, alkylamino, dialkylamino, alkoxy, cycloalkyl, cycloalkyloxy, aryl, heteroaryl, aryloxy, or heteroaryloxy group; or Z together with Y, M, G, or R 10 form an optionally substituted carbocyclic ring, or an optionally substituted heterocyclic ring containing 1 to 5 heteroatoms, where Z is linked to Y, M, G, or R 10 ; preferably Z is linked to Y, M, G, or R 10 by any number of atoms up to about 20 atoms.
- M can be an optionally substituted alkyl, alkenyl, or alkynyl group; an optionally substituted alkyl, alkenyl, or alkynyl group of 1 to 5 carbon atoms; an optionally substituted alkylene, an alkenylene, or alkynylene group; or an optionally substituted alkylene, alkenylene, or alkynylene group of 1 to 5 carbon atoms.
- R 10 can be an aryl, a heteroaryl group, a fused aryl, a fused heteroaryl group or optionally substituted versions of these groups; or R 10 can be any one of structures (4a), (4b), (4c), or (4d):
- R 11 , R'n, R 12 , any OfR 13-17 , or any OfR 14-17 can be H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy or heteroaryloxy; or independently R 11 , R'n, Ri2, any OfR 13-17 , or any OfR 14-17 can be H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; or independently R
- Some embodiments include compounds of structure (5) where:
- a 1 can be H, or lower alkyl, or A 1 and Rn, together form a ring of 3-5 atoms;
- R la can be H;
- R ⁇ can be a lower alkyl group, or together with A 1 forms a ring of 3 to 5 atoms;
- Y can be an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, heteroalkynyl, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of the aforementioned groups, hydroxy substituted versions of the aforementioned groups, or Y together with Z la , Z 11 ,, or R 1O forms an optionally substituted carbocyclic ring, or an optionally substituted heterocyclic ring containing 1 to 5 heteroatoms, where Y can be linked to Z la , Zn,, or R 10 ; preferably Y is linked to Z la , Zn 3 , or R 1O by any number of atoms up to about 20 atoms.
- Z la and Zn can independently be an H, hydroxy, amino, alkylamino, dialkylamino, alkoxy, aryloxy, or heteroaryloxy group; or Z la , Z lb; together with Y or R 10 form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z 1 a or Zn,, is linked to Y or R 10 ; preferably Z la or Zn,, is linked to Y or R 10 by any number of atoms up to about 20 atoms.
- M can be an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms.
- R 10 can be aryl, a heteroaryl group, or Rio can be anyone of structures (4a), (4b), (4c), or (4d):
- X 2 can be a heteroatom in structures (4a) or 4(b) or X 2 is a carbon-carbon bond as illustrated in structures (4c) or (4d), and independently groups R 11 , R' ⁇ , R 12 , any of R 13-17 , or any OfRi 4-17 can be H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; or independently Rn, R' ⁇ , R 12 , any OfR 13-17 , or any OfR 14-17 can be H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino
- any OfR 13-17 , or any of R 14 - I7 preferably these groups are linked by any number of atoms up to about 20 atoms.
- Some embodiments of compounds of structure (5) have a K d as determined by the methods described, for example, in Example 1 of less than 100 micromolar, preferably less than 1 micromolar, and even more preferably less than 0.1 micromolar.
- Some embodiments include compounds of structure (5) where:
- a 1 can be H, methyl, ethyl, or A 1 and R ⁇ together form a ring of 3-5 atoms.
- R la can be H; R ⁇ can be a methyl or ethyl group, or together with A 1 forms a ring of 3 to 5 atoms.
- Y can be an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, heteroalkynyl, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of the aforementioned groups; hydroxy substituted versions of the aforementioned groups; or Y together with Z la , Z 113 , or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z la , Z 1 ⁇ or Rj 0 ; preferably Y is linked to Z la , Zy 0 , or R 10 by any number of atoms up to about 20 atoms.
- Z 1 a and Zy 0 can independently be an H, hydroxy, amino, alkylamino, diakylamino, alkoxy, aryloxy, or heteroaryloxy group; or Z la , Z 1 ⁇ together with Y or R 1O form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z la or Z 1 ⁇ is linked to Y or R 10 ; preferably Z la or Z 11 ,, is linked to Y or R 10 by any number of atoms up to about 20 atoms.
- M can be an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms.
- R 10 can be a fused aryl, a fused heteroaryl group, or preferably R 10 is anyone of structures (4a), (4b), (4c), or (4d):
- R 11 , R' ⁇ , R 12 , any OfR 13-17 , or any OfR 14-17 can be H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; or independently R 11 , R' ⁇ , R 12 , any of R 13-17 , or any OfR 14-17 can be H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyal
- Some embodiments include compounds of structure (5) where:
- a 1 can be H, or a methyl group
- R la is H
- R ⁇ can be a methyl or ethyl group.
- Y can be an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, heteroalkynyl, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of the aforementioned groups, hydroxy substituted versions of the aforementioned groups, or Y together with R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to R 10 ; preferably Y is linked to R 10 by any number of atoms up to about 20 atoms.
- Zi a and Z ⁇ can independently be an H, hydroxy, alkoxy, or aryloxygroup.
- M can be methylene, an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms.
- G can be absent (a bond), or a heteroatom including -O-; or -NH-,
- R 10 can be an aryl, a heteroaryl group, or in some embodiments R 10 can be a structure of formula (4a):
- R 11 , R 12 , or any OfR 14-17 can be H, or optional substituents including halogen, alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; or independently R 11 , R 12 , or any OfR 14-17 can be H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; or independently R 11 , R 12 , or any OfR 14 .
- R 17 can be acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R 12 , or any OfR 14-17 can be contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z la , Z 1I ,, M, G, Rn, R 12 , or any OfR 14-17 , preferably these groups are linked by any number of atoms up to about 20 atoms.
- IAP binding compounds or IAP binding cargo molecules in various embodiments of formula (2), (3), or (5) may be used in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of a cancer or cellular proliferation condition (including developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders).
- the IAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) can be used in the preparation of a drug for treating cancer or a cellular proliferation disorder condition in a ready to use form.
- the drug can be administered to a patient for treating or preventing cancer or a cellular proliferation disorder, hi ready to use form refers to the compounds being presentable for sale and may include the compounds in a tablet, liquid, or other form for administration, suitable packaging, instructions, and other items.
- One embodiment of the invention is a method of treating cells or tissue that can include administering to cells having a proliferation disorder, for example HeLa cells known to overexpress IAP (other cells may include but are not limited to those with developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders), an amount of the LAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) that is effective to reduce or eliminate the cellular proliferation disorder in the sample of cells or tissue.
- a proliferation disorder for example HeLa cells known to overexpress IAP (other cells may include but are not limited to those with developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders)
- an amount of the LAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) that is effective to reduce or eliminate the cellular proliferation disorder in the sample of cells or tissue.
- a further embodiment of the present invention is a method of treating disorders associated with cell proliferation, including, but not limited to proliferative disorders and diseases.
- Such methods include administration of the compounds of the present invention alone or in combination with other active agents, including pharmaceuticals and chemotherapeutic agents.
- the dimmers of LAP binding compounds of the present invention may be administered alone or in combination with chemotherapeutic agents as is disclosed in commonly owned U.S. Provisional Application No. 60/692,111, which is incorporated herein by reference in its entirety.
- IAP binding compounds as well as pharmaceutically acceptable salts and solvates thereof, may be formulated as pharmaceutical compositions or as diagnostic agents, or both. These pharmaceutical compositions and diagnostic agents may be used for treatment and detection of cell proliferative disorders, as well as in screening assays for the discovery and development of additional diagnostic and therapeutic agents for modifying cell proliferation and detecting cell proliferative disorders.
- the present invention includes an assay for use in high throughput screening or rational drug design of LAP binding compounds that can, like the Smac tetrapeptide or its homologs in other species, bind to a BLR domain of an LAP thereby modifying, and preferably relieving IAP-mediated suppression of apoptosis.
- the binding of test compounds can be used in the design of IAP binding compounds and IAP binding cargo molecules for the identification, prevention, and treatment of diseases related to cell proliferation.
- the LAP binding cargo molecule or compounds in embodiments of the present invention can bind to proteins such as through the BIR domain of an LAP.
- the LAP binding molecule interacts with the BUG domain of the protein XLAP or BLR2 domain of DIAPl.
- the LAP binding molecule can interact with the protein through a specific binding groove of the BLR domain.
- the assay includes the steps of providing a labeled LAP binding compound or an LAP binding-cargo molecule of structure (2), (3), or (5), that binds to the appropriate BLR domain of the LAP, wherein preferably at least one measurable feature of the labeled LAP binding compound changes as a function of the labeled LAP binding compound being bound to the LAP or free in solution.
- the assay may further include contacting the BLR domain of an LAP with the labeled LAP binding compound under conditions enabling binding of the labeled LAP binding compound with the BLR domain, thereby forming a labeled BLR-bound LAP binding compound complex having the measurable feature.
- the labeled BLR-bound LAP binding compound complex may be contacted with other peptides, LAP binding compounds, or test compounds being developed, to measure the binding of the peptides, LAP binding compounds, or test compound for the BLR domain by measuring the displacement of the labeled LAP binding compound from the labeled BLR-bound LAP binding compound complex. Displacement of the labeled LAP binding compound from the labeled BLR-bound LAP binding compound complex by the peptides, LAP binding compounds, or test compound can be determined by measuring the change in the measurable feature of the labeled LAP binding compound, thereby determining if the test compound is capable of binding to the BLR domain of the LAP and the strength of the interaction.
- the present invention relates to the treatment of cell proliferation conditions and diseases and more specifically conditions where the activity of LAP in cells, tissues or an individual is abnormal.
- the invention features molecules that are LAP binding compounds of structure (2), (3), or (5), that bind to IAPs such as but not limited to XIAP, c-IAPl, C-IAP2, ML- IAP and survivin in cells.
- the mimetic molecules optionally include an integral or linked cargo portion that can include a therapeutic or diagnostic functionality.
- the LAP binding compound molecules may be administered to cells, a tissue, or a patient in need of treatment or detection for a cell proliferation condition or disease.
- the need for treatment can be identified by contacting cells or a tissue, preferably from the patient, with an IAP binding molecule having a detectable label or cargo that changes when the molecule binds to an IAP in the tissue or cells.
- the binding of the IAP binding compound molecule with the IAP in the cells can be used to modify a cell proliferation condition or disease or it may be combined with other therapeutic treatments such as radiation therapy.
- the activity of IAP in the cells or the progress of a course of treatment for a cell proliferation condition or disease may be measured with an IAP binding cargo molecule having a detectable label.
- a method of selectively identifying neoplastic or cancer cells in a mixed population of cells includes contacting the mixed cell population with a cell permeable IAP-binding cargo molecule of structure (2), (3), or (5), under conditions enabling the IAP-binding cargo molecule to bind a protein like an IAP within the neoplastic cells, thereby selectively identifying the neoplastic cells by a detectable property of the IAP binding cargo molecule, and in some embodiments a change in a detectable property of the LAP binding cargo molecule upon complexation with LAP in the neoplastic cells.
- the cells may be cultured cells or primary cells from a patient (human or animal). Alternatively, the cells may be present within the patient, and the contacting accomplished by introducing the IAP-binding cargo molecule into the patient.
- the cargo portion of the molecule comprises a dye label.
- the cargo portion of the molecule can be, but is not limited to, an NMR-active nucleus or an MRI contrast agent.
- the selective identification of tissues or cells having LAP is performed through nuclear magnetic resonance or magnetic resonance imaging.
- the labeled IAP-binding cargo molecule comprises a radioisotope and the selective identification is performed through positron emission tomography.
- Another aspect of the invention features a method of selectively damaging or inducing apoptosis in neoplastic cells by killing some or all of the neoplastic cells in a mixed population of cells.
- the method includes contacting a sample of the mixed cell population with an IAP-binding cargo molecule of formula (2), or (3), or (5).
- the LAP binding portion of the molecule or the cargo portion of the molecule can include a moiety or substituent that is directly or indirectly toxic to cells such as but not limited to a radioisotope or a photosensitizing agent.
- the LAP binding portion of the molecule binds to a protein like an LAP within the neoplastic cells, where the toxic moiety of the IAP-binding cargo molecule directly or indirectly exerts its toxic effect, thereby damaging or killing at least a portion the neoplastic cells in a mixed population of cells.
- the LAP binding cargo molecule binds to an LAP protein, such as XLAP, C-LAPl, C-IAP2, ML-LAP, or survivin, preferably it binds to a BLR surface groove of an LAP protein. In some embodiments the LAP binding molecule binds to the BLR3 surface groove of an XIAP protein.
- the LAP binding cargo molecule of structure (2), (3), or (5) can permeate or be transfected into the cells and can, for example, be used to displace one or more LAP proteins from caspases in the cells or displace a protein like Smac sequestered by LAPs.
- the LAP binding cargo molecule can have a detectable property which is modified upon chemical, physical, or a combination of these interactions, of the LAP binding molecule with the LAP protein in the cells.
- This composition is useful as a control for monitoring the presence of LAP in the cells undergoing treatment or for use as a standard in the detection of abnormal LAP levels in a sample of cells.
- the detectable property may be the emission of light by the cargo portion of the molecule which changes when the LAP bonding portion of the molecule binds to an LAP protein.
- the LAP binding compounds or LAP binding cargo molecules of structure (2), (3), or (5) in embodiments of the invention may be characterized by having an LAP binding constant K d .
- K d is less than about 10 ⁇ M
- K d is less than about 1 ⁇ M
- K d is less than about 0.1 ⁇ M as determined by the methods described in Example 1 or equivalents of these methods known to those skilled in the art.
- Molecules of formula (2), (3), or (5) having a K d of less than about 10 ⁇ M can be used in an in vitro binding assay with the BLR domain of an LAP and in some embodiments the BLR3 domain of XLAP.
- the LAP binding cargo molecule and preferably the cargo portion of the molecule includes but is not limited to a fluorogenic group, a radioisotope, or other chromogenic group.
- the LAP binding cargo molecule may include another peptide or peptidomimetic unit (e.g., dimer).
- the LAP binding cargo molecule may include an NMR-active nucleus or an MRI contrast agent and the selective identification of the cargo portion of the molecule performed through nuclear magnetic resonance or magnetic resonance imaging.
- the one or more cells in the composition may include but are not limited to cells from a bodily fluid, tissue, tumor, fibroid, neoplastic cells, stem cells, nervous system cells or any combination of these from an animal, a mammal, or a human.
- the cells in the composition may be taken from tissue suspected of exhibiting an abnormal level of LAP based upon physical examination, motor skill tests, or detection by palpation of a lump in a part of the body.
- the composition may include one or more pharmaceutically acceptable
- Another embodiment of the present invention is a method of identifying LAP in cells that includes monitoring a mixture of one or more LAP binding cargo molecules comprising structure (2), (3), or (5), or dimers thereof, with one or more sample cells for the presence of a detectable label from an IAP binding cargo molecule or a change in a detectable property of one or more of the LAP binding cargo molecules in the mixture.
- the detectable property of the LAP binding cargo molecule changes upon formation of a complex between the LAP binding cargo molecule and the BLR domain of an LAP protein
- the LAPs may include but are not limited to XLAP, C-LAPl, C-IAP2, ML-LAP, or survivin in the sample cells.
- the LAP may be bound to a caspase, other proteins like Smac, or combinations of these within the cell.
- Monitoring may be performed on cells and an LAP binding cargo molecule in a fluid sample, a flowing fluid, or fluids following purification.
- This invention may be used to detect abnormal expression, over or under expression, of LAP in cells and the indication of abnormal expression used to begin a course of treatment of the cells.
- the LAP binding cargo molecule is used to detect overexpression of LAPs in cells.
- the method may further include the act of comparing a change in a detectable property of one or more LAP binding cargo molecules mixed with one or more control cells to the detectable change in the property of the one or more LAP binding cargo molecules mixed with one or more sample cells.
- the comparison may be related to the amount or activity of LAP in the sample cells.
- the method may include the act of combining one or more LAP binding cargo molecules with one or more cells including but not limited to sample cells, control cells, or various combination of these cells.
- the monitoring may use the absorption or emission of radiant energy by the mixture of LAP binding cargo molecules and the cells, including but not limited to magnetic resonance, fluorescence, chemiluminesence, magnetic resonance imaging, and positron emission tomography.
- the change in the detectable property of one or more of the LAP binding cargo molecules in the mixture chemically, and or physically binding to the LAP in the cells is a change in the intensity of fluorescent emission of the LAP binding molecule.
- a change occurs in the fluorescent emission of one or more IAP binding cargo molecules capable of displacing IAP from caspases or Smac from IAPs in the sample cells.
- a method of treating cells of the present invention includes identifying the expression of IAP in cells and administering an amount of a cell permeable IAP-binding cargo molecule or other therapeutic to the cells to modify the activity of IAP in the cells.
- the LAP - binding cargo molecule may be formulated with a pharmaceutically acceptable excipient. For example, following identification of abnormal levels of LAP in a sample of cells, (optionally by comparison to a control sample of cells), purified Smac, an LAP binding compound, or an LAP binding cargo molecule, may be added to the cells to induce apoptosis.
- This invention can be used to identify cells in need of treatment, treat the cells, and mom ' tor the progress of the treatment of the cells having the abnormal LAP levels.
- the act of identifying cells having abnormal IAP expression includes monitoring a mixture of one or more LAP binding cargo molecules with one or more sample cells for a change in a detectable property of one or more of the LAP binding cargo molecules.
- the detectable property changes upon formation of a complex between the LAP binding molecule and LAP in the sample cells.
- Another embodiment of the present invention is an article or kit that includes packaging material containing a composition of LAP binding compound or an LAP binding cargo molecule of formula (2), (3), or (5) or a dimer thereof.
- the packaging material has a label that indicates how the LAP binding cargo composition can be used for administration, treatment, or detecting levels of LAP in a sample of cells.
- the label may further indicate how the LAP binding cargo molecule or another LAP binding cargo molecule included in a pharmaceutical composition can be used to treat cells where an abnormal level of LAP expression is determined.
- An embodiment of the present invention is a method of selectively identifying neoplastic cells in a mixed population of cells. Ln the method a sample of the mixed cell population is contacted with one or more LAP-binding cargo molecules of formula (2), (3), or (5) or dimers thereof under conditions enabling the LAP-binding cargo molecule to bind LAP within the neoplastic cells and thereby selectively identifying the neoplastic cells.
- the cells may include but are not limited to cultured cells, cells that are removed from a subject by biopsy, or cells from a fluid.
- the contacting may be performed by introducing the labeled LAP-binding cargo molecule into a tissue sample or a tissue in a living subject possessing or suspected of possessing the neoplastic cells.
- the LAP-binding cargo molecule can have a dye label cargo portion and preferably the dye is a fluorogenic dye.
- the labeled IAP-binding cargo molecule may have an NMR-active nucleus or a contrast agent and the selective identification performed through nuclear magnetic resonance or magnetic resonance imaging.
- the labeled IAP-binding cargo molecule may have a cargo portion of the molecule that is a radioisotope and where the selective identification performed through positron emission tomography.
- the IAP binding cargo molecule may be formulated with pharmaceutically acceptable excipients and optionally other therapeutic agents for modifying apoptosis in the sample of cells.
- Another embodiment of the present invention is a method of selectively damaging or killing neoplastic cells in a mixed population of normal and neoplastic cells.
- the method includes contacting a sample of the mixed cell population with a cell permeable IAP-binding cargo molecule of formula (2), (3), or (5) or dimers thereof including an agent that is directly or indirectly toxic to cells, preferably the cargo portion of the molecule is an agent that is directly or indirectly toxic to cells.
- the agent directly or indirectly exerts its toxic effect, thereby damaging or killing at least a portion the neoplastic cells.
- the method may use a toxic agent that is a radioisotope.
- the method may use a photosensitizing toxic agent and the selective damaging or killing is performed by exposing the cell population to light.
- the LAP binding molecules of the present invention and pharmaceutical compositions containing these compounds can bind to IAP's (Inhibitor of Apoptosis Proteins) such as but not limited to XIAP, c-IAPl, C-IAP2, survin, and LIVIN/ML-IAP. These compounds may include diagnostic or therapeutic moieties or substituents as part of the binding portion of the molecule or linked to the binding portion of the molecule.
- IAP binding cargo molecules may be arbitrarily divided to include an IAP binding portion and a cargo portion.
- the IAP binding portion of the molecule interacts with an IAP protein, preferably the BIR domain of an IAP protein, and may be a monomer or dimer.
- the IAP binding portion of the molecule interacts with the BIR3 surface groove of XIAP.
- the cargo portion of the molecule may be part of the backbone or IAP binding portion of the molecule or the cargo portion may be chemically bonded to the IAP binding portion of the molecule.
- the cargo portion of the molecule may include but is not limited to structures, moieties, and substituents for imaging, therapeutics, probes, labels, or markers.
- the cargo portion and LAP binding portion of the molecule may be connected by a chemical bond to the LAP binding portion including but not limited to amide, ester, or disulfide bonds, chelation, or by a linking group such as diaminobutane or ethylene glycol and its oligomers where it is desirable to separate the LAP binding portion of the molecule from the cargo portion of the molecule.
- a linking group such as diaminobutane or ethylene glycol and its oligomers where it is desirable to separate the LAP binding portion of the molecule from the cargo portion of the molecule.
- One or more atoms in any portion of the LAP binding cargo molecule may be a radioisotope and used for detection or treatment.
- the cargo portion may constitute a second monomer, thereby forming a dimer molecule, via a linking group.
- the binding portion of the LAP binding compound confers IAP target protein specificity to the molecule and the cargo portion can provide a functional group to the molecule for monitoring or evaluating the location of the molecule or providing a therapeutic to that location within a cell sample or a tissue in a mammal.
- the LAP binding compounds may be used to displace sequestered proteins in cells, for example caspase-3,7 or 9 or Smac interacting with an IAP, so that the released protein can be used to promote apoptosis within the cell.
- the cargo portion of the molecule is linked to the LAP binding portion
- the cargo portion may be bonded or chemically linked to any portion of the LAP binding portion of the molecule so that it does not adversely affect LAP binding, cell permeance or transfection into cells.
- the molecule While chemical interaction between the LAP binding portion and the cargo portion of the molecule may occur, the molecule is made so that the molecule's cell permeance, its LAP binding property, and function of the cargo portion are not adversely affected by their combination.
- the suitability of any LAP binding cargo molecule made by the method disclosed may be tested against fluorescently labeled peptide [AbuRPF-K(5-Fam)-NH 2 ] in cells such but not limited to renal cell carcinoma, non-small cell lung cancer, HeLa cells, or others known to overexpress LAP, or other cells having a proliferation disorder.
- the LAP binding molecules of the present invention are capable of permeating cells of interest, binding to LAP in the cells, and optionally delivering the cargo to the cells.
- Embodiments of compounds of structure (2), (3), (5) include 2-substituted pyrrolidine- 1-carbonyls, or 2, 4- independently substituted pyrrolidine- 1- carbonyls that have a K d as determined by methods described, for example, in Example 1 of less than 100 micromolar, preferably less than 1 micromolar, and even more preferably less than 0.1 micromolar.
- the pharmaceutically active compounds of the invention are sometimes referred to herein as drugs, to highlight their therapeutic utility in promoting apoptosis by binding LAPs.
- another embodiment of the invention utilizes the compounds as diagnostic agents, for detection of LAP in vitro, in situ or in vivo, or for IAP binding assays.
- the compounds of the invention are detectably labeled, for example, with a fluorophore.
- Another embodiment of the invention utilizes the compounds as targeting agents, i.e., by incorporating into their structure tumor cell-killing or other anti-tumor or therapeutic agents, such as radionuclides.
- drugs refer to pharmaceutically/biologically active (i. e., LAP- binding) compounds of the invention, for use as therapeutic, prophylactic, or diagnostic agents.
- heteroatom refers to nitrogen, oxygen, sulfur, other atoms or groups where the nitrogen, sulfur and other atoms may optionally be oxidized, and the nitrogen may optionally be quaternized. Any heteroatom with unsatisfied valences is assumed to have hydrogen atoms sufficient to satisfy the valences. Ln some embodiments, for example where the heteroatotn is nitrogen and includes a hydrogen or other group to satisfy the valance of the nitrogen atom, replacement of the nitrogen in a similar structure by another heteroatom, for example by oxygen, will result in the hydrogen or group previously bonded to the nitrogen to be absent.
- heteroatom may include but is not limited to for example -O-, -S-, -S(O)-, - S(O) 2 -, -N-,-N(H)-, and -N(C 1 -C 6 alkyl).
- alkyl refers to a saturated straight, branched, or cyclic hydrocarbon having from about 1 to about 30 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein).
- Lower alkyl group refers to a saturated straight, branched, or cyclic hydrocarbon having group of 1 to 10 carbon atoms, more preferably 1 to 5 carbon atoms and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein.
- Alkyl groups include, but are not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopropyl, methylcyclopropyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, cyclooctyl, adamantyl, 3-methylpentyl, 2,2- dimethylbutyl, and 2,3-dimethylbutyl.
- substituted alkyl refers to a saturated straight, branched, or cyclic hydrocarbon having from about 1 to about 30 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein) having from 1 to 5 substituents.
- substituted lower alkyl group refers to a saturated straight, branched, or cyclic hydrocarbon of 1 to 10 carbon atoms, more preferably 1 to 5 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein) having from 1 to 5 substituents.
- alkylene radical as used herein includes reference to a di-functional saturated branched or unbranched hydrocarbon radical containing from 1 to 30 carbon atoms, and includes, for example, methylene (-CH 2 -), ethylene (-CH 2 CH 2 - ), propylene (-CH 2 CH 2 CH 2 -), 2-methylpropylene (-CH 2 CH(CH 3 )CH 2 -), hexylene (-(CH 2 ) 6 -), and the like.
- Lower alkylene includes an alkylene group of 1 to 10, more preferably 1 to 5, carbon atoms.
- Substituted alkylene radicals includes reference to a di-functional saturated branched or unbranched alkylene radical or group having 1-30 carbon atoms and having from 1 to 5 substituents.
- Lower substituted alkylene radicals refer to to a substituted alkylene radical group, having 1-10 carbon atoms, preferably having 1-5 carbon atoms, and having from 1 to 5 substituents.
- Substituents can include but are not limited to those for the alkyl groups.
- alkenyl radical as used herein includes reference to a branched, cyclic hydrocarbon, or unbranched hydrocarbon radical of 2 to 30 carbon atoms containing at least one carbon-carbon double bond, such as ethenyl, n-propenyl, isopropenyl, n-butenyl, isobutenyl, t- butenyl, octenyl, decenyl, tetradecenyl, hexadecenyl, eicosenyl, tetracosenyl and the like.
- lower alkenyl includes an alkenyl group of 2 to 10 carbon atoms, preferably 2 to 5 carbon atoms, containing at least one carbon-carbon double bond.
- the one or more carbon-carbon double bonds may independently have a cis or trans configuration.
- Substituted alkenyl radical refers to an alkenyl radical or lower alkenyl group having from 1 to 5 substituents that can include but are not limited to those for the alkyl groups.
- alkenylene radical includes reference to a difunctional branched or unbranched hydrocarbon radical or group containing from 2 to 30 carbon atoms and at least one carbon-carbon double bond.
- “Lower alkenylene” includes an alkenylene group of 2 to 10, more preferably 2 to 5, carbon atoms, containing one carbon-carbon double bond.
- Substituted alkenylene radical refers to an alkenylene radical or lower alkenyl group having from 1 to 5 substituents that can include but are not limited to those for the alkyl groups.
- alkynyl radical or group refers to straight or branched chain hydrocarbon radical having 2 to 12 carbon atoms and at least one triple bond, some embodiments include alkynyl groups of 2 to 6 carbon atoms that have one triple bond.
- a substituted alkynyl will contain one, two, or three substituents as defined for substituted alkyl groups.
- Alkynylene includes reference to a difunctional branched or unbranched hydrocarbon chain containing from 2 to 12 carbon atoms and at least one carbon-carbon triple bond; some embodiments include an alkynylene groups of 2 to 6 carbon atoms with one triple bond.
- a substituted alkynylene will contain one, two, or three substituents as defined for substituted alkyl groups.
- halo or halogen refers to any halogen, such as I, Br, Cl or F.
- cyano refers to the -C ⁇ N group.
- aryl radical or group refers to an optionally substituted, mono or bicyclic aromatic ring radicals having from about 5 to about 14 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 6 to about 10 carbons being preferred.
- Non-limiting examples or aryl groups include, for example, phenyl and naphthyl.
- a substituted aryl group will contain one or more substituents as defined for substituted alkyl groups.
- Aralkyl radical refers to alkyl radicals bearing an aryl substituent and have from about 6 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 6 to about 12 carbon atoms being preferred.
- Aralkyl groups can be optionally substituted. Non-limiting examples include, for example, benzyl, naphthylmethyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- a substituted arylalkyl group will contain one or more substituents on the aryl or alkyl group as defined for substituted alkyl groups.
- Cycloalkylaryl radical or group refers to a cycloalkyl radical fused to an aryl group, including all combinations of independently substituted alkyl cycloalkylaryls, the cycloalkyl and aryl group having two atoms in common.
- fused cycloalkylaryl groups used in compounds of the present invention may include 1-indanyl, 2-indanyl, 1 -(1,2,3,4- tetrahydronaphthyl), and the like.
- Tetrahydronaphthyl more specifically refers to those univalent radicals or groups derived from fused polycyclic hydrocarbons including all combinations of independently substituted alkyl tetrahydronaphthyls.
- radicals may have a point of attachment at (C 1 ) or equivalently (C 4 ) in structure (11), or position labeled (C 2 ) and equivalently (C 3 ) in structure (Ha).
- the chiral carbon atoms C 1-4 in tetrahydronaphthlene and its alkyl substituted derivatives may have either an (R) or (S) configuration.
- Cycloalkyl radical or group more specifically includes reference to a monovalent saturated carbocyclic alkyl radical consisting of one or more rings in their structures and having from about 3 to about 14 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 3 to about 7 carbon atoms being preferred.
- Multi-ring structures may be bridged or fused ring structures.
- the rings can optionally be substituted with one or more of the substituents for the alkyl groups.
- Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, and adamantyl.
- a substituted cycloalkyl group will contain one or more substituents as defined for substituted alkyl groups.
- Cycloalkylalkyl radical more specifically refers to alkyl radicals bearing an cycloalkyl substituent and having from about 4 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 6 to about 12 carbon atoms being preferred and can include but are not limited to methyl- cyclopropyl, methylcyclohexyl, isopropylcyclohexyl, and butyl-cyclohexyl groups.
- Cycloalkylalkyl radical or group can be optionally substituted with one or more substituents for the alkyl groups including but not limited to hydroxy, cyano, alkyl, alkoxy, thioalkyl, halo, haloalkyl, hydroxyalkyl, nitro, amino, alkylamino and dialkylamino.
- Exemplary aroyl groups include benzoyl and naphthoyl.
- p can be independently the integer 0, 1, 2, or 3.
- Aryloxy radical refers to optionally substituted mono or bicyclic aromatic radical having from about 5 to about 14 carbon atoms and an (aryl-O-) radical group wherein aryl is as previously defined.
- aryloxy radicals include but are not limited to that illustrated by the radical of formula (12).
- Optional substituents on the aryl ring in the aryloxy radical may include but are not limited to hydrogen, alkyl, halogen, hydroxy, alkoxy, alkoxycarbonyl or other substituents.
- Embodiments of IAP binding compounds of the present invention can include an optionally aryloxy group like the phenoxy radical linked to the pyrrolidine ring as illustrated but not limited to compounds in Table 5.
- Some embodiment of IAP binding compounds include include a phenoxy radical where the K ⁇ as determined by methods described, for example, in Example 1 is less than about 0.1 micromolar.
- alkoxy and alkoxyl refer to an optionally substituted (alkyl-O) radical or group wherein alkyl is as previously defined.
- exemplary alkoxy radicals or groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, cyclopropyl-methoxy, and heptoxy.
- Alkoxy radicals can also include optionally substituted alkyl in the alkylO- group.
- Alkoxy can include including optionally substituted aryl groups as previously defined and illustrated by the non-limiting radical of formula (13).
- a "lower alkoxy” group refers to an optionally substituted alkoxy group containing from one to five carbon atoms.
- Polyether refers to a compound or moiety possessing multiple ether linkages, such as, but not limited to, polyethylene glycols or polypropylene glycols.
- Polyalkylethers refers to alkyls interconnected by or otherwise possessing multiple ether linkages as illustrated by the non-limiting structure of formula (85) in Scheme VIII of Example 16.
- Arylalkyloxy means an arylalkyl-0 — group in which the arylalkyl group is as previously described. Exemplary arylalkyloxy groups include benzyloxy (C 6 HsCH 2 O-) radical (BnO-), or 1- or 2-naphthalenemethoxy.
- Optional substituents on the aryl ring in the benzyloxy radical may include but are not limited to hydrogen, alkyl, halogen, hydroxy, alkoxy, and alkoxycarbonyl or other substituents as defined for the alkyl group.
- Arylamino radical refers to optionally substituted mono or bicyclic aromatic radical having from about 5 to about 14 carbon atoms and an (-NH(aryl)) radical group wherein aryl can be optionally substituted as previously defined for alkyl.
- Optional substituents on the aryl ring in the arylamino radical may include but are not limited to hydrogen, alkyl, halogen, hydroxy, alkoxy, and alkoxycarbonyl.
- a example of an arylamino group is the anilino radical or group.
- Amino refers to an -NH 2 group and alkylamino refer to a radical (-NH R') group wherein R 1 is H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or optionally substituted versions of these as previously defined.
- alkylamino radical groups include methylamino, ethylamino, n- propylamino, i-propylamino, n-butylamino, and heptylamino.
- the benzylamino radical refers to the arylamino group C 6 HsCH 2 NH-, the aryl group may have optional substituents including but are not limited to hydrogen, alkyl, halogen, hydroxy, alkoxy, and alkoxycarbonyl or other substituents.
- Dialkylamino includes reference to a radical (-NR 1 R"), wherein R' and R" can be each independently be an H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or optionally substituted versions of these as previously defined.
- dialkylamino radicals include, but are not limited to, dimethylamino, methylethylamino, diethylamino, di(l-methylethyl)amino, and the like.
- Heteroaryl includes reference to a monovalent aromatic radical or group having one or more rings incorporating one, two or three heteroatoms within the ring (chosen from nitrogen, oxygen, or sulfur). These heteroaryls can optionally have hydrogen atoms substituted with one or more other substituents. Examples of these heteroaryl radicals include optionally substituted benzofurans, benzo[b]thiophene 1 -oxide, indoles, 2- or 3-thienyls or thiophenyls, thiazoyls, pyrazines, pyridines, or the structures of (4a) or (4b).
- the structure of formula (ElO) with derivatives listed in Table 9, can include a fused ring R 10 with a heteroatom X 2 (N, O, or other) and substituents such as R 11 or R' ⁇ including but not limited to hydrogen, halogens, optionally substituted heteroaryls like pyridine,benzofuran, indoles, thiazoyl, pyrazine, an alkoxyheteroaryl like methoxy pyridine, or other groups.
- heteroalkyl, heteroalkylene, heteroalkenyl, heteroalkenylene, heteroalkynyl, and heteroalkynlene include reference to alkyl, alkylene, alkenyl, alkenylene, alkynyl, and alkynlene radicals or groups, in which one or more of the carbon atoms have been replaced or substituted with atoms such as but not limited to single or multiply bonded nitrogen, sulfur, oxygen, or these atoms having one or more hydrogens to satisfy the valancy requirements of the atom.
- substitutions can be used to form molecules having functional groups including but not limited to amines, ethers, and sulfides.
- a non-limiting example of a heteroalkynyl group is illustrated by the group -CH(Me)OCH 2 C ⁇ CH.
- Heterocycloalkyl radical include reference to a monovalent saturated carbocyclic radical or group consisting of one or more rings, incorporating one, two or three heteroatoms (chosen from nitrogen, oxygen or sulfur), which can optionally be substituted with one or more substituents.
- Heterocycloalkenyl includes reference to a monovalent unsaturated carbocyclic radical consisting of one or more rings containing one or more carbon-carbon double bonds where carbon atoms are replaced or substituted for by one, two or three heteroatoms within the one or more rings, the heteroatoms chosen from nitrogen, oxygen, or sulfur, the heterocycloalkenyl can optionally be substituted with one or more substituents.
- Various groups used in the molecules of the present invention can have one or more hydrogens atoms substituted for chemical moieties or other substituents.
- each moiety R' or R" can be, independently include of H, alkyl, cycloalkyl, aryl, heteroaryl, aralkyl or optionally-substituted alkyl, cycloalkyl, aryl, heteroaryl, araalkyl.
- the substituents can be chosen so that IAP binding compounds of formula (2), (3), or (5) that contain them have a K d as measured by methods described, for example, in Example 1 of less than about 100 micromolar, in some embodiments have a K ⁇ j of less than 1 micromolar, and in other embodiments have a K d of less than 0.1 micromolar.
- the substituents can be chosen so that IAP binding compounds of formula (2), (3), or (5) that contain them have an EC 50 as measured by methods described, for example, in Example 2 of less than about 0.5 micromolar, in some embodiments have an EC 50 of less than about 0.06 micromolar.
- the substituents can be chosen so that LAP binding compounds of formula (2), (3), or (5) that contain them have a binding constant K d of less than about 1 micromolar, preferably less than 0.1 micromolar and an EC 50 of less than about 1 micromolar, preferably less than about 0.5 micromolar, and in some embodiments an EC 50 of less than about 0.06 micromolar.
- Amino acids can be used in the IAP binding compound compounds of this invention and may include the 20 naturally-occurring amino acids, known artificial amino acids such as beta or gamma amino acids, and amino acids containing non-natural side chains, and/or other similar monomers such as hydroxyacids.
- the amino acids used in the LAP binding compounds of the present invention are the 20 naturally-occurring amino acids.
- the amino acids or artificial amino acids are chosen with the effect that the corresponding LAP binding compound binds IAPs, and preferably binds the BLR domain of an LAP, and the resulting LAP binding compound is permeable to the cell.
- a non-limiting example of such an amino acid includes the use of Abu (2-aminobutyric acid) as an amino acid in the LAP binding cargo molecule.
- Abu (2-aminobutyric acid)
- the N-terminal amino acid is Ala or Abu.
- any of the enantiomers, D or L and more generally R or S configuration, or diastereoisomers may optionally be used in the LAP binding compound.
- any variable occurs more than one time in any constituent or in any formula, its definition in each occurrence is independent of its definition at every other occurrence. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
- substituents such as A 1 , A 2 , R la , and Ri b , R 2 , Xi, Y, Z, M, G, or R 10 , may be chosen independently so that compounds of structure (2), (3), or (5) are not a tripeptide or a tetrapeptide of amino acids, for example AVPI or AVP.
- a 1 is H, lower alkyl, or optionally-substituted lower alkyl group, an N-acyl derivative like acylamino or acylalkylamino, t-butoxycarbonyl, acetyl, formyl, carbamoyl, alkylene, or other;
- R la and R ⁇ are separately H, lower alkyl, optionally-substituted lower alkyl, lower alkylene, optionally substituted lower alkylene group; or A 1 together with either R la or R ⁇ form an optionally substituted heterocycloalkyl group of 3 to 6 atoms as illustrated by some of the non-limiting embodiments of compounds in Table 5.
- Y can be H, an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, heteroalkynyl, a cycloalkyl group of 3 to 7 carbon atoms, aryl, heteroaryl, arylalkyl; optionally-substituted versions of the aforementioned groups such as optionally substituted alkyl group, optionally substituted alkyl group of 1 to 10 carbon atoms, an optionally substituted branched alkyl group of 1 to 10 carbon atoms, an optionally substituted alkenyl group, an optionally substituted alkynyl group, an optionally substituted heteroalkynyl group, an optionally substituted cycloalkyl group or 3 to 7 carbon atoms, an optionally substituted aryl group, an optionally substituted heteroaryl group, an optionally substituted arylalkyl;
- Z can be H, alkyl, hydroxy, amino, alkylamino, diakylamino, alkoxy, cycloalkyl, cycloalkyloxy, aryl, heteroaryl, aryloxy, heteroaryloxy; optionally substituted versions of these groups; optionally substituted versions of these groups including one or more hydroxyl groups; or Z together with Y, M, G, or R 1O can form an optionally substituted carbocyclic ring, or an optionally substituted heterocyclic ring containing 1 to 5 heteroatoms, where Z is linked to Y, M, G, or R 10 ; preferably Z is linked to Y, M, G, or R 1O by any number of atoms up to about 20 atoms.
- Z is an alkyl, hydroxy, amino, alkylamino, dialkylamino, alkoxy, cycloalkyl, cycloalkyloxy, aryl, heteroaryl, aryloxy, or heteroaryloxy group.
- the stereochemistry of the Z substituent or group may be indicated using a bold wedged bond to show a Z group coming out of the plane of the page or a dashed wedged bond to show a Z group behind the plane of the page, hi embodiments of (3), the IAP binding molecule may have a structure where the Z group is directed out of the plane of the page, the LAP binding molecule may have a structure where the Z group is directed behind the plane of the page, or the LAP binding molecule may include a mixture where the Z group is a combination of these.
- M can be an optionally- substituted alkyl, alkenyl, or alkynyl group; M can be an optionally-substituted alkyl, alkenyl, or alkynyl group of 1 to 5 carbon atoms; M can be an optionally-substituted alkylene, alkenylene, or alkynylene group; or an optionally-substituted alkylene, alkenylene, or alkynylene group of 1 to 5 carbon atoms.
- M is a diradical alkylene like the methylene group linked at one end of the methylene group the 2 position of the pyrrolidine ring and at the other end of the methylene group to an aryl group, a heteroaryl group, or an optionally substituted heteroaryl group like a benzofuran or indole group, or optionally substituted versions of groups of structure (4a-d).
- R 10 can be an aryl, a heteroaryl group, a fused aryl, or a fused heteroaryl group.
- R 10 can be a substituted aryl, a substituted heteroaryl group, a substituted fused aryl, or a substituted fused heteroaryl group.
- R 1O can be any one of structures (4a), (4b), (4c), or (4d):
- Rn, R'n, Rj 2 , any OfR 13-17 , or any OfR 14-17 can be H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy, heteroaryloxy, other substituents or optionally substituted versions of these groups.
- Rj 1 or R'n is a heteroaryl group
- it can be a 2- or 3-thienyl SC 4 H 3 - (thiophenyl) group, pyridine, pyrazine or optionally substituted versions of these.
- R 12 can be an aryl or a heteroaryl group, such as but not limited to benzofuran, indole, benzo[&]thiophene-l-oxide or benzo[ ⁇ ]thiophene- 1,1 -dioxide or optionally substituted versions of these.
- X 2 is either -O- or -S(O) k -, for the integer k which can independently be 0, 1, or 2, R 12 is absent.
- R 11 , R'n, R 12 , any OfR 13-17 , or any OfR 14-17 can be H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, carboxyalkyl, alkyl carboxyalkyl, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy.
- R 11 , R'n, R 12 , any OfR 13- 17 , or any OfR 14-17 can be acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R' 11; R 12 , any OfR 13-17 , or any of R 14-17 can be contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z, M, G, Rn, R'n, R12, any OfR 13-17 , or any OfR 14-17 , preferably these groups are linked by any number of atoms up to about 20 atoms.
- Li some embodiments R 1O can be cycloalkyl, aryl, heterocycloalkyl, heterocycloalkenyl, heteroaryl, or optionally substituted embodiments of these.
- R 10 can be the group:
- R 1 Q can be an optionally substituted aryl group having substituents for example but not limited to hydrogen, chloro, bromo, alkyl, alkylene, alkoxy, or combinations of these.
- LAP binding compounds of formula (3) include compounds of structure (5) where:
- Ai is H, or lower alkyl, or Ai and Rn, together form a ring of 3-5 atoms.
- R la is H and R ⁇ can be lower an alkyl group, or together with Ai forms a ring of 3 to 5 atoms.
- Y can be an alkyl group, an alkyl group of 1 to 10 carbon atoms, a branched alkyl group of 1 to 10 carbon atoms, an alkynyl group, heteroalkynyl, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of the aforementioned groups, and/or hydroxy substituted versions of the aforementioned groups, or Y together with Z la , Zu,, or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Zi 8 , Z 1 ⁇ or R 10 ; preferably Y is linked to Z la , Z 113 , or R 10 by any number of atoms up to about 20 atoms;
- Z 1 a and Z ⁇ > can independently be an H, hydroxy, amino, alkylamino, diakylamino, alkoxy, aryloxy, or heteroaryloxy group; or Zi 3 , or Z 1 I 3 , together with Y or R 10 form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z la or Z 1 ),, is linked to Y or R 10 ; preferably Z la or Z ⁇ , is linked to Y or R 10 by any number of atoms up to about 20 atoms;
- M can be an optionally-substituted alkyl or an optionally-substituted alkylene group of 1 to 5 carbon atoms.
- IAP binding compounds or molecules of structure (2), (3), or (5) can be prepared by various processes, which are described by the non-limiting Schemes in the Examples and which also form part of the subject matter of the present invention.
- These IAP binding molecules may be prepared from molecules of structure (6a) or (6b):
- the IAP binding molecule may have a structure where the Z or M group is directed out of the plane of the page, the LAP binding molecule may have a structure where the Z or M group is directed behind the plane of the page, or the IAP binding molecule may include a mixture where the Z or M group includes a combination of these.
- Structures of formula structure (6a) or (6b) may be prepared from compounds such as but not limited to pyrrolidines like (1) in Scheme I or (29) in Scheme IVa using the procedures or similar processes described herein.
- the structures of formula structure (6a) or (6b) may be further reacted to yield IAP binding molecules of structure (2), (3), or (5) by treatment with an N-Boc-amino acid or other suitable amine containing moiety that includes A 1 , A 2 , R la , or R lb or combinations of these as described herein.
- Certain acidic or basic compounds of the present invention may exist as zwitterions. All forms of the compounds, including free acid, free base and zwitterions, are contemplated to be within the scope of the present invention. It is well known in the art that compounds containing both amino and carboxyl groups often exist in equilibrium with their zwitterionic forms. Thus, any of the compounds described herein throughout that contain, for example, both amino and carboxyl groups also include reference to their corresponding zwitterions.
- an IAP binding cargo molecule or other IAP binding compound of the invention may be either a compound of one of the formulae herein described, or a stereoisomer, prodrug, pharmaceutically acceptable salt, hydrate, solvate, acid salt hydrate, or isomorphic crystalline form thereof.
- Pharmaceutically acceptable salt refers to those salts of the LAP binding cargo molecules and LAP binding compounds of structure (2), (3), or (5) or dimers thereof which retain the biological effectiveness and properties of the free bases or free acids, cell permeation and LAP binding, and which are not biologically or otherwise undesirable.
- the desired salt may be prepared by methods known to those of ordinary skill in the art, such as treatment of the compound with an inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like; or with an organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
- an inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like
- organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic
- the desired salt may also be prepared by methods known to those of ordinary skill in the art, such as the treatment of the compound with an inorganic base or an organic base.
- Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
- Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, 2- dimethylaminoethanol, 2-diethylaminoethanol, trimethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
- basic ion exchange resins such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine,
- the LAP binding cargo molecules or their pharmaceutically acceptable salts may include pharmaceutically acceptable solvent molecules within their crystal lattice. Where the solvent is water, the compounds may form hydrates, in the case of other solvents and in particular organic solvents such as but not limited to ethanol the compounds may form solvates.
- the IAP binding cargo molecules or IAP binding compounds of structure (2), (3), or (5) and its homologs may be formulated, isolated, or purified as solvates.
- the compounds employed in the methods of the present invention may exist in prodrug form.
- Prodrug includes any covalently bonded carriers which release the active parent drug, for example, as according to formula (2) or other formulas or compounds employed in the methods of the present invention in vivo when such prodrug is administered to a mammalian subject.
- prodrugs are known to enhance numerous desirable qualities of pharmaceuticals (e.g. solubility, bioavailability, manufacturing, etc.) the compounds employed in the present methods may, if desired, be delivered in prodrug form.
- the present invention contemplates methods of delivering prodrugs.
- Prodrugs of the compounds employed in the present invention, for example formula (2) may be prepared by modifying functional groups present in the compound in such a way that the modifications are cleaved, either in routine manipulation or in vivo, to the parent compound.
- prodrugs include, for example, compounds described herein in which a hydroxy, amino, or carboxy group is bonded to any group that, when the prodrug is administered to a mammalian subject, cleaves to form a free hydroxyl, free amino, or carboxylic acid, respectively.
- Examples include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups; and alkyl, carbocyclic, aryl, and alkylaryl esters such as methyl, ethyl, n-propyl, iso-propyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclopropyl, phenyl, benzyl, and phenethyl esters, and the like.
- the compounds employed in the methods of the present invention may be prepared in a number of ways well known to those skilled in the art.
- the compounds can be synthesized, for example, by the methods described in the specification and example, or variations thereon as appreciated by the skilled artisan.
- AU processes disclosed in association with the present invention are contemplated to be practiced on any scale, including microgram, milligram, gram, multi-gram, kilogram, multi-kilogram or commercial industrial scale.
- IAP binding compounds of structure (2), (3), or (5) can be mixed or combined with pharmaceutically acceptable excipients or treated by lyophilization. These pharmaceutical compositions may be administered topically, locally or systemically to a sample of cells, a tissue, or patient. Topical or local administration can allow for greater control of application of the pharmaceutical compositon.
- the IAP binding molecules or compounds including structure (2), (3), or (5) singularly or in combination, can be mixed with an appropriate pharmaceutical carrier prior to administration.
- Examples of generally used pharmaceutical carriers and additives that can be used to form pharmaceutical, diagnostic, or therapeutic composition of the IAP binding molecules may include but are not limited to conventional diluents, binders, lubricants, coloring agents, disintegrating agents, buffer agents, isotonizing agents, preservants, anesthetics and the like.
- Pharmaceutical carriers that may be used include but are not limited to water, saline, ethanol, dextran, sucrose, lactose, maltose, xylose, trehalose, mannitol, xylitol, sorbitol, inositol, serum albumin, gelatin, creatinine, polyethylene glycol, non- ionic surfactants (e.g.
- polyoxyethylene sorbitan fatty acid esters polyoxyethylene hardened castor oil, sucrose fatty acid esters, polyoxyethylene polyoxypropylene glycol) and similar compounds.
- Pharmaceutical carriers and excipients as well as IAP binding molecules may also be used in combination.
- Stereoisomers are compounds having identical molecular formulae and nature or sequence of bonding but differing in the arrangement of their atoms in space and include optical and geometrical isomers.
- Compounds of the present invention, or their pharmaceutically acceptable salts can have one or more asymmetric carbon atoms or other asymmetric atoms in their structure, and may therefore exist as single stereoisomers, enantiomers, diastereoisomers, racemates, and mixtures of enantiomers or diastereomers. These compounds may also include geometric isomers.
- stereoisomers, racemates and mixtures thereof the LAP binding compounds and IAP binding cargo molecules of the present invention are intended to be within the scope of this invention unless the specific stereochemistry or isomeric form is specifically indicated. It is well known in the art how to prepare and isolate such optically active forms. For example, mixtures of stereoisomers may be separated by standard techniques including, but not limited to, resolution of racemic forms, normal, reverse- phase, and chiral chromatography, preferential salt formation, recrystallization, and the like, or by chiral synthesis either from chiral starting materials or by deliberate synthesis of target chiral centers.
- LAP binding molecules of structures (2), (3), or (5) that contain chiral centers and the molecules can be in the form of a single enantiomer or as a racemic mixture of enantiomers.
- chirality i.e., relative stereochemistry
- substituents or groups is indicated in the structure using a bold wedged bond to indicate a substituent coming out of the plane of the page and a dashed wedged bond to indicate a substituent behind the plane of the page, hi other cases the stereochemistry is not indicated and such structures are intended to encompass both the enantiomerically pure or purified forms of the compound shown as well as a racemic mixture of enantiomers.
- protecting groups may contain protecting groups during the course of synthesis.
- Protecting groups are chemical functional groups that can be selectively appended to and removed from functionalities, such as amine, hydroxyl groups or carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention.
- Protecting groups include the benzyloxycarbonyl group and the tert-butyloxycarbonyl group.
- protecting group refers to any group which when bound to one or more hydroxyl, amino, carboxyl or other groups of the compounds (including intermediates thereof such as the aminolactams, aminolactones, etc.) prevents reactions from occurring at these groups and which protecting group can optionally be removed by conventional chemical or enzymatic steps to reestablish the hydroxyl, amino, carboxyl group for use in an IAP binding compound.
- removable blocking group is not critical and preferred removable hydroxyl or amine blocking groups include conventional substituents such as allyl, benzyl, acetyl, chloroacetyl, thiobenzyl, benzylidine, phenacyl, t-butyl-diphenylsilyl, t-butyl carbamate, benzyl carbamate and any other group that can be introduced chemically onto a hydroxyl, amine, or other functionality and later selectively removed either by chemical or enzymatic methods in mild conditions compatible with the nature of the product.
- the cargo portion of the molecule may be part of the backbone or IAP binding portion of the molecule or the cargo portion may be chemically bonded or linked to the LAP binding portion of the molecule.
- the cargo portion may be another unit of the formula (2), (3) or (5), linked by a linking group to the first unit, thereby forming a dimer and may further comprise an additional cargo portion.
- the cargo portion may also be any of the substituents A 1 , A 2 , R 1 a , Rib, Y, R 2 , or Z in molecules of formula (2), preferably the cargo portion is linked to Y, R 2 , or Z in molecules of formula (2).
- the cargo portion may be any of the substituents Ai, Ri a , Rib, Rio, Y, M, G, or Z (includes Z la and Zi b ), preferably the cargo portion includes a substituent linked at Y, Z (include Zi a and Zu 3 ), or Rio-
- the cargo portion of the molecule may include but is not limited to structures, moieties, and substituents for imaging, therapeutics, detectable groups, probes, labels, or markers.
- the cargo portion and IAP binding portion of the molecule may be connected by a chemical bond to the IAP binding portion including but not limited to amide, ester, or disulfide bonds, chelation, or by a linking group such as diaminobutane or ethylene glycol and its oligomers where it is desirable to separate the IAP binding portion of the molecule from the cargo portion of the molecule.
- One or more atoms in any portion of the IAP binding cargo molecule may be a radioisotope and used for detection or treatement.
- One aspect of the present invention comprises an assay that can be used to test the binding affinity of a library of IAP binding compounds for their ability to bind to the BIR domain of an inhibitor of apoptosis protein (IAP), for example the BIR3 domain of mammalian XIAP.
- the assay may be based on a detectable label, which can be a fluorogenic dye molecule that is the cargo portion of an IAP-binding cargo molecule.
- the detectable label may be any of the substituents in the molecules of formula (2), (3), or (5).
- the detectable label may be linked to the substituent R 2 , or linked to the substituents R 2a-C supra in molecules having the structure of formula (2)
- a detectable label included in a molecule of formula (2), (3), or (5) can be a dye such as is a fluoro genie dye whose emission is sensitive to the environment of the dye.
- the detectable label portion of an IAP binding cargo molecule may also be an NMR- active nucleus or a contrast agent and the selective identification is performed through nuclear magnetic resonance or magnetic resonance imaging.
- the detectable label in an IAP-binding cargo molecule may also be a radioisotope and where the selective identification is performed through positron emission tomography.
- the cargo portion of the molecule may also be used to destroy cells through a toxic effect of the cargo portion of the molecule.
- the molecule of stucture (2), (3), or (5) packs into the BIR domain of an IAP.
- the molecule of structure (2), (3), or (5) has a fluorgenic dye as a cargo substituent, preferably the packing of the molecule of structure (2), (3), or (5) into the groove of the BIR of an IAP causes a large shift in emission maximum and intensity of the dye when the environment of the LAP binding cargo molecule changes from water to the hydrophobic pocket or binding in or near the groove of the IAP. If a molecule (e.
- An LAP binding cargo molecule of formula (2) having a detectable lable may be complexed to an LAP and used to screen other IAP binding compounds.
- the IAP binding cargo molecule of structure (2), (3), or (5) or dimers thereof may comprise any suitable therapeutic molecule or detectable label, such as but not limited to a fluorophore, radioisotope, or NMR active nucleus, such that binding of the IAP binding cargo molecule to the BIR domain of an LAP, and preferably the BIR3 groove of XIAP, is not detrimentally affected by the presence of the detectable label or therapeutic in the IAP binding cargo molecule.
- the molecule is cell permeable.
- a non-limiting example of a detectable label which may be coupled to the LAP binding compounds and LAP binding cargo molecules of structure (2), (3), or (5) is the fluorogenic dye 6-Bromoacetyl-2- dimethylaminonaphthalene (badan) dye.
- Badan is a fluorogenic dye whose sensitivity to environmental changes has previously been made use of to probe protein binding interactions.
- the LAP binding cargo molecules of structure (2), (3), or (5) can be used in an assay of test compounds that can bind to the BLR domain of an LAP. These molecules may be used for example to relieve suppression of apoptosis or to release sequestered proteins like Smac from LAPs in cells.
- a high-throughput, cell-free assay, for compounds of structure (2), (3), or (5) may also be prepared using a fluorescently labeled peptide like (AbuRPF-K(5-Fam)-NH 2 ).
- a wide variety of LAP binding compounds may be screened or assayed for their ability to bind to the BLR domain of IAPs.
- LAP binding molecules with greater binding ability than the naturally- occurring Smac, or LAP binding molecules that can release sequesterd Smac from LAP in cells can be identified by such an assay.
- These compounds may be developed as therapeutic agents, pharmaceutical compositions for the modification, and preferably the promotion, of apoptosis in treatment of diseases or pathological conditions in which cell proliferation plays a role.
- These identified compounds may be used as prophylactics and can also be modified to include detectable labels or toxic agents.
- the assay may be further used in high throughput screening of large panels of compounds generated by combinatorial chemistry or other avenues of rational drug design.
- the fluorescence assay can be used to test the binding of a library of LAP binding cargo molecules modeled on the binding of Smac and its homologs, and preferably the binding of Smac N-terminus, to the surface pocket of the BLR3 region of XIAP.
- the results of such screening make it possible to parse the contribution of each moiety in the structure of the LAP binding cargo molecule to the total binding of the interaction. For example, by comparing the 08
- the present invention features, LAP binding compounds and methods of their use for binding to Inhibitor of Apoptosis Proteins (IAPs), including but not limited to XIAP, C-IAPl, C-LAP2, survivin, ML-LAP or combinations of these.
- IAPs Inhibitor of Apoptosis Proteins
- One function of IAPs is to suppress programmed cell death, whereas Smac, or LAP binding compounds of structure (2), (3), or (5) can be used to relieve that suppression.
- the mammalian LAP binding protein Smac is dependent upon binding of its N-terminal four residues to a featured surface groove in a portion of XIAP referred to as the BLR3 domain.
- An LAP binding cargo molecule such as those of formula (2), (3), or (5), may be used to relieve XIAP-mediated or other LAP-mediated suppression of apoptosis in mammalian cells and can optionally provide a functional group having a detectable property or a therapeutic function to the cell.
- LAP binding cargo molecule such as those of formula (2), (3), or (5), maybe used or to release sequestered proteins like Smac from LAPs in cells.
- One embodiment of the invention is a method of using versions of LAP binding compounds of formula (2), (3), or (5) that can include administering to abnormal cells or tissue, which may be known to overexpress LAP as well as other cell lines related to developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders such as but not limited to for example SK-OV-3 cells, HeLa cells, or other cells, an amount of the LAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) that is effective to reduce, eliminate, or otherwise treat the sample of cells.
- An amount of the LAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) can be administered to normal cells or tissue as a control.
- the amount of compound of formula (2), (3), or (5), combinations of these, or combinations that include other therapeutic compounds that are effective to reduce the proliferation condition can be determined from changes in the optical density of treated and control cell or tissue samples.
- the administered compound of structure (2), (3), or (5), in some embodiments include those with an EC 50 as measured using the method described, for example, in Example 1 for the LAP binding compounds of less than about 1 micromolar, in other embodiments an EC 50 of less than about 0.5 005/025208
- the EC 50 for the administered IAP binding compounds of structure (2), (3), or (5) can be less than about 0.06 micromolar.
- IAP binding compound refers to a molecule that provides tertiary binding or activity with the BIR-containing protein's functional domain (e.g., binding motif or active site) of an LAP.
- LAP binding compounds can be non-peptide agents such as small molecule drugs of structure (2), (3), or (5) or that include molecules of structure (2), (3), or (5). Knowing the structural features and bonding of naturally-occurring IAP-binding cargo molecules such as Smac and its homologs, it is advantageous to make LAP binding compounds that have similar or improved binding compared to the core IAP-binding N-terminal tetrapeptides of Smac and its homologs.
- LAP binding cargo molecules of structure (2), (3), or (5) in various embodiments of the invention is that compounds of this size and structure can be prepared by large scale syntheses, they can be chemically modified to have improved solubility in aqueous solution, have improved cell permeance, and provide ease of delivery to selected targets in vivo.
- IAP-binding cargo molecules of the invention can include amino acids as well as molecules where the amino acids are modified to produce LAP binding compounds by elimination, replacement or modification, of one or more naturally occurring side chains of the genetically encoded amino acids.
- Replacement can include exchange of one or more of the L amino acids with D amino acids.
- groups such as alkyl, lower alkyl, cyclic 4-, 5-, 6-, to 7-membered alkyl, amide, lower alkyl amide, di(lower alkyl) amide, lower alkoxy, hydroxy, carboxy and the lower ester derivatives thereof, and with 4-, 5-, 6-, to 7-membered heterocyclics can be used.
- proline analogs can be made in which the ring size of the proline residue is changed from 5 members to 4, 6, or 7 members or substituents are added at various positions (2, 3, 4, or 5) on the ring.
- the substituents may be an ester group R 2 , or an aryloxy group Z.
- Cyclic groups can be saturated or unsaturated, and if unsaturated, can be aromatic or non-aromatic.
- Heterocyclic groups may be used in as a side group in R 2 in the molecules of formula (2), (3), or (5).
- the heterocyclics can contain one or more nitrogen, oxygen, and/or sulphur heteroatoms.
- heterocyclic groups include the furazanyl, fiiryl, imidazolidinyl, imidazolyl, imidazolinyl, isothiazolyl, isoxazolyl, morpholinyl (e.g. morpholino), oxazolyl, piperazinyl (e.g. 1-piperazinyl), piperidyl (e.g. 1-piperidyl, piperidino), pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolidinyl (e.g.
- IAP binding compounds may also have amino acid residues that have been chemically modified by phosphorylation, sulfonation, biotinylation, or the addition or removal of other moieties.
- LAP binding cargo molecules are synthetic compounds having a three-dimensional structure (i.e. a "peptide motif) based upon the three-dimensional structure of a selected Smac peptide or homolog.
- the peptide motif provides the IAP binding compound with the desired biological activity, i.e., binding to LAP, wherein the binding activity of the LAP binding compound compound is not substantially reduced, and is often the same as or greater than the activity of the native peptide on which the LAP binding compound is modeled.
- LAP binding cargo molecules of the present invention can have additional beneficial characteristics that enhance their therapeutic application, such as decrease cost for synthesis, increased cell permeability, enhanced stability to radiological elements, greater affinity and/or avidity for target IAPs, and prolonged biological half-life.
- the backbone can include various chemical bonds such as ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, to modify LAP binding in the LAP binding cargo compounds.
- caspases are cytosolic enzymes, diagnostic, imaging, prophylactic, and therapeutic LAP binding cargo molecules that chemically bind with the LAP proteins preferably cross cell membranes.
- the cell membrane-permeant LAP binding cargo molecule complexes of the present invention are preferably those that can confer the desired intracellular translocation and LAP binding properties to the LAP binding cargo molecules.
- these LAP binding cargo molecules are characterized by their ability to confer transmembrane translocation and internalization of a complex LAP binding cargo molecule of structure (2), (3), or (5) when administered to the external surface of an intact cell, tissue or organ.
- IAP binding cargo molecules of the present invention may be demonstrated by a variety of detection methods such as, for example, fluorescence microscopy, confocal microscopy, electron microscopy, autoradiography, or immunohistochemistry.
- the IAP binding cargo molecule of structure (2), (3), or (5) can bind to IAPs in the cell and can but is not limited to competitively displacing IAPs bound to a caspases in the cells or releasing Smac sequestered with IAPs in the cells.
- the IAP binding cargo molecule chemically, physically, or by a combination of these, binds to an IAP protein and may displace it from a mature caspase or Smac protein in a cell.
- the physical interaction between the LAP binding portion of the LAP binding cargo molecule and an LAP protein can be used to modify apoptosis in cells.
- LAP binding molecules or cargo molecules of formula (2), (3), or (5) can have an LAP binding portion which can, for example, displace a molecule or polypeptide such as a mature caspase or fluorescently labeled peptide (AbuRPF-K(5-Fam)-NH 2 ) from the BLR domain of an IAP.
- LAP binding portion which can, for example, displace a molecule or polypeptide such as a mature caspase or fluorescently labeled peptide (AbuRPF-K(5-Fam)-NH 2 ) from the BLR domain of an IAP.
- LAP binding molecules of formula (2), (3), or (5) having a binding constant K d as measured by the methods described, for example, in Example 1 for the displacement of (AbuRPF-K(5-Fam)-NH2) from the BLR domain of an LAP can be less than about 10 ⁇ M, in some embodiments K d can be less than about 1 ⁇ M, and in still other embodiments K d can be less than 0.1 micromolar under the assay conditions described in the examples.
- the labeled IAP-binding cargo molecule of structure (2), (3), or (5) may include any suitable detectable label, including fluorophores, chromophores, fluorescent nanoparticles, and other dyes, isotopes, radioisotopes, metals, small molecules and the like.
- the label is linked or bonded to the LAP binding portion of the molecule, the label preferably does not interfere substantially with the cell permeance or binding of the molecule to LAP and permits its use in diagnostic or therapeutic applications.
- Ln selecting a label preferably a detectable property of the label changes with the binding of the LAP binding cargo molecule to the BLR domain of an LAP protein.
- the detectable property of the label may change because the interaction of the label with the cellular environment changes when the molecule binds to LAP thereby enhancing or diminishing the property.
- IAP-binding cargo molecules can also find utility as therapeutic agents.
- the binding of the IAP binding cargo molecule to LAP in cells can be used to modify apoptosis in cells in need of treatement.
- an LAP binding cargo molecule where the cargo portion is radiolabeled may be used for radiation therapy.
- radioactive atoms may be administered to a tumor, tissue, or other population of cancer cells that overexpress LAP protein.
- the LAP in the tumor becomes bonded to the LAP binding cargo molecule with the radionuclei.
- IAP-binding cargo molecules may be designed to incorporate a dye that is active in photodynamic therapy. Other such therapeutic utilities will be apparent to those skilled in the art.
- Cells being evaluated to detect abnormal levels of IAP in the cells may be mixed and optionally incubated with an LAP binding cargo molecule in a fluid sample in a vessel or wells, a flowing fluid, or fluids following purification. These samples may be monitored for changes in a detectable property of the LAP binding cargo molecule.
- flow cytometry is a method for analyzing cells labeled with a fluorescent probe molecule on a flow cytometer. Ln a flow cytometer the cells pass single-file through a focused laser beam where they emit fluorescence from the probe within the cell that can be detected by the photomultiplier tubes of the cytometer.
- Cells with abnormal expression, high or low, of IAP may be contacted and optionally incubated with LAP binding cargo molecules of structure (2), (3), or (5) having a fluorescent probe cargo portion.
- the binding of the LAP binding cargo molecules to the LAP protein in the cells may be detected by the flow cytometer.
- the intensity of the fluorescence emission can be measured, digitized, and stored on a computer disk for analysis and comparison to the fluorescent emission from control cells, samples of cells being treated, or other cell samples whose IAP expression is to be determined.
- a method of screening for LAP proteins in cells with a molecule that binds the BLR domain in an LAP protein includes combining an LAP binding cargo molecule of formula (2), (3), or (5) and the LAP proteins from cells, under conditions wherein the LAP binding cargo molecule and LAP protein can combine. It may include the step of incubating a sample of cells with an LAP binding cargo molecule. LAP binding by the molecule, an indication of the presence of LAP in the cells may be determined by monitoring a detectable binding property of the LAP binding cargo molecule. A change in the detectable property of the LAP binding molecule may be used to determine the expression of LAP in the cells.
- the IAP binding cargo molecule can be used to bind the IAP and relieve IAP-mediated inhibition of caspase activity in the cell.
- the LAP binding cargo molecule of structure (2), (3), or (5) can be used to release the sequested Smac or other protein from the LAP and modify apoptosis within the cells.
- other LAP binding cargo molecules may be administered to the cells.
- These additional LAP binding cargo molecules may have different binding affinity for the LAP and may optionally include a cargo portion that is a therapeutic agent such as a radioisotope.
- the IAP-binding cargo molecules may be utilized in various assays to screen for and identify compounds capable of acting as agonists or antagonists of the LAP -caspase protein or LAP-Smac interactions within cells.
- LAP binding cargo molecules which can disrupt IAP-caspase interaction, antagonists of this interaction are expected to be useful as pro-apoptotic drugs for treatment of cell proliferative diseases such as cancer.
- Agonists of this interaction may be be useful as anti-apoptotic drugs for treatment of diseases where inhibition of apoptosis is needed, e.g., degenerative diseases such as Alzheimer's disease.
- a living system may include plants, animals, single and multicellular organisms, and insects.
- the term mammal includes humans and all domestic and wild animals, including, without limitation, cattle, horses, swine, sheep, goats, dogs, cats, and the like.
- An effective amount refers to that amount of a an LAP binding cargo molecule of formula (2), (3), or (5) of the present invention which, when administered to a sample of one or more cells including a tissue, or a living system such as an animal, preferably a mammal, in need thereof, is sufficient to effect detection of LAP in tissue or cells, prophylaxis of tissue or cells, or therapeutic treatment of IAP in the cells or tissue, preferably those in a living system.
- the amount of a compound of the present invention which constitutes a therapeutically effective amount that modifies or promotes apoptosis in one or more cells including a tissue, or a subject will vary depending on the compound, the disease-state and its severity, and the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
- a diagnostically effetive amount is an amount of an LAP binding cargo molecule sufficient to permit detection of LAP in cells or tissue and may for example vary depending upon the location of the cell or tissue and the stability of the IAP binding-cargo molecule.
- a prophylactically effective amount is an amount of an IAP binding cargo molecule that prevents the occurance of a disease state and may be determined for example by prophylactic administration of IAP binding cargo molecules to cells, tissue, or test animals with controls and then exposing these to conditions known to induce abnormal cellular proliferation and then determining the prophylactically effective amount of the IAP binding cargo molecule.
- Treating or treatment of a disease-state in a sample of cells, a tissue, a mammal, and particularly in a human can include detecting the presence of disease in the cells using compounds of structure (2), (3), or (5) of the present invention and where a disease is detected, optionally followed by administration of compounds of the present invention to the one or more cells, to an animal or tissue including human subjects, to modify and preferably promote apoptosis.
- the disease-state in the case of over expression of IAP proteins in cells may be alleviated by the inhibition of an IAP-caspase interaction or an IAP-Smac interaction by administering IAP binding cargo molecules of the present invention to the cells thereby causing regression of the disease-state.
- the treatment can also include: preventing the disease-state from occurring in a mammal.
- a mammal that is predisposed to a disease-state characterized by inhibition of apoptosis, but the mammal has not yet been diagnosed as having the disease; an effective amount of the IAP binding compounds of the present invention may be administed to cells or the patient to inhibit the disease-state or arrest its development.
- molecules of structure (2), (3), of (5) can be administered as a composition to provide systemic distribution of the IAP binding molecules such as by oral, buccal or parenteral administration in the mammal or human.
- the administration can be included in a method of treating mammals, especially humans, suffering from a proliferation disorder or that are at risk of a proliferation disorder.
- “At risk” refers to mammals like persons whose genotype, family history, or other risk factors indicates a greater than normal likelihood that the person will suffer from a proliferation disorder if left untreated.
- the expression of IAP in cells can be detected in patients without the need for surgery. Accordingly, the present invention encompasses compounds and methods for detecting intracellular biochemical activities in living systems such as, whole animals, tissues, or 25208
- IAP binding cargo molecules of this invention which translocate into cells, and which are detectable in living cells at distances removed from the cells by the presence of intervening tissue.
- the methods and compositions can be used for identifying cells or tissue having abnormal expression of IAP in a combination of one or more cells or tissues; and administering an effective amount of an IAP -binding cargo molecule to bind with the IAP in the sample cells and modify the activity of the IAP in the cells or tissue.
- tissues to which the methods and compositions of the present invention can be applied include, for example, cancer cells, in particular, central nervous system tumors, breast cancer, liver cancer, lung, head and neck cancer, lymphomas, leukemias, multiple myeloma, bladder cancer, ovarian cancer, prostate cancer, renal tumors, sarcomas, colon and other gastrointestinal cancers, metastases, and melanomas.
- diseases, conditions or disorders where modification of apoptosis or abnormal LAP activity are involved and to which the methods and compositions of the present invention can be applied include, but are not limited to infection, inflammation, neurodegenerative diseases such as Alzheimer disease and Parkinson's disease.
- a proliferation disorder may include a disorder in which LAP activity inhibits apoptosis in cells receiving an apoptotic stimulus.
- Apoptosis may be promoted in a sample of cells by administering to the cells an amount of an LAP -binding cargo molecule effective to stimulate apoptosis in the cells.
- the cells may be cultured cells, cells from within a tissue, and the tissue preferably is located within a living organism, preferably an animal, more preferably a mammal, and most preferably a human. These latter embodiments are carried out by formulating the IAP-binding cargo molecules of the invention in a therapeutically effective amount as a pharmaceutical preparation for administration to a mammalian subject. Such a pharmaceutical preparation constitutes another aspect of the present invention.
- the ability of a pharmaceutical agent to simulate or inhibit apoptosis may be tested in a cell-free activity assay of downstream targets of LAP. Ln the absence of an IAP- binding cargo molecule, LAP itself can for example interact with Smac or inhibit the activity of caspases, thereby arresting apoptosis.
- assays include, but are not limited to, direct caspase- 9 activity assays and caspase activation assays (cleavage of procaspases).
- an IAP-binding cargo molecule of the invention having a pre-determined level of activity in such assays, is used as a positive control and, optionally, a corresponding molecule known not to be active in the assay is used as a negative control.
- Assays can be conducted using these controls, and the cells undergoing the treatment evaluated on relief of inhibition of Smac or caspase activity by IAP in the presence of the IAP binding cargo molecule of structure (2), (3), or (5).
- Cells that undergo apoptosis can be differentiated from normal cells by distinct morphological changes or by molecular markers, such as cleavage of chromosomes into nucleosome ladders (detected by nuclear DNA staining).
- LAP binding cargo molecules of the invention are those that bind LAP (inhibitor of apoptosis protein), specifically the BLR domain of LAP, more specifically the BLR3 binding groove of XIAP. This biological activity may be measured with respect to any LAP, including but not limited to XIAP, c-IAPl, c- LAP2, survivin, ML-IAP, and DLAP.
- Binding constants were measured using fluorescence polarization as described by Zaneta Nikolovska-Coleska, Renxiao Wang, Xueliang Fang, Hongguang Pan, York Tomita, Peng Li, Peter P. Roller, Krzysztof Krajewski, Naoyuki Saito, Jeanne Stuckey and Shaomeng Wang, in "Development and Optimization of a Binding Assay for the XIAP BLR3 Domain Using Fluorescence Polarization", Analytical Biochemistry 2004, 332 ,261-273).
- test LAP binding compounds at various concentrations for binding measurements were mixed with 5 nM fluorescently labeled peptide (AbuRPF-K(5-Fam)-NH 2 ) and 40 nM of XIAP- BLR3 for 15 minutes at room temperature in 100 ⁇ L of 0.1M Potassium Phosphate buffer, pH 7.5 containing 100 ⁇ g/ml bovine ⁇ -globulin.
- the polarization values (mP) were measured on a ViCtOr 2 V using a 485 ran excitation filter and a 520 nm emission filter.
- IC 50 values were determined from the plot using nonlinear least-squares analysis using GraphPad Prism.
- K d values of competitive inhibitors were calculated using the equation described by by Zaneta Nikolovska-Coleska et al. based upon the measured IC 5 0 values, the K d value of the probe and XLAP BLR3 complex, and the concentrations of the protein and probe in the competition assay.
- This example illustrates use of compounds of embodiments of the present invention that can be used in a method of treating cells.
- the method using these LAP binding compounds can include administering to abnormal cells, which may be known to overexpress LAP as well as other cell lines related to developmental disorders, cancer, autoimmune diseases, as well as neuro-degenerative disorders such as but not limited to for example SK-OV-3 cells, HeLa cells or other cells, an amount of the LAP binding compounds or LAP binding cargo molecules in various embodiments of formula (2), (3), or (5) that is effective to reduce, eliminate, or otherwise treat the sample of cells.
- the MTT assay is an example of an assay that has been used for measuring cell growth as previously described (Hansen, M. B., Nielsen, S. E., and Berg, K. J. Immunol. Methods 1989, 119, 203-210) and incorporated herein by reference in its entirety. Briefly, SK-OV-3 cells were seeded in 96-well plates in McCoy's medium containing 10% fetal bovine serum albumin (20,000 per well) and incubated overnight at 37 °C. Next day, test compounds were added at various concentrations typically from about 10 to about 0.0001 ⁇ M and the plates were incubated at 37 °C for an additional 72 hrs. This incubation time was optimal for measuring inhibitory effects of different analogs.
- CS Cell survival
- the EC 50 defined as the drug concentration that results in 50% CS, was derived by calculating the point where the dose-response curve crosses the 50% CS point using GraphPad Prism.
- Representative results for IAP binding compounds are:
- N- Methylmorpholine (0.1 mL) was added to reaction mixture. After 10 min, pyrrolidine 5 (0.17 g, 0.48 mmol) in NMP (5 mL) was added. After 16 h, the reaction mixture was diluted with EtOAc and washed with dilute aqueous NaHCO 3 , IN HCl, water, and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The crude amide was purified by flash silica gel chromatography (1:1 hexane/EtOAc) to afford 0.23 g (92%) of 6 as a colorless oil.
- the white precipitate was removed by filtration and washed with DCM.
- the clarified filtrate was washed successively with IM NaOH, water, and brine.
- the organic phase was dried with anhydrous Na 2 SO 4 , filtered, and concentrated.
- the crude ether was purified by flash silica gel chromatography (3:1 hexane/EtOAc) to afford 0.18 g (45%) of 9 as a colorless oil.
- Trifluoroacetic acid (2 mL) was added at ambient temperature to a solution of 9 (0.18 g, 0.43 mmol) in DCM (10 mL). After 1 h, the solution was concentrated to dryness and the crude product was dissolved in EtOAc. The organic solution was washed with aqueous NaHCO 3 , brine, dried over anhydrous MgSO 4 , filtered, and concentrated. The crude amine (10) was used without further purification (0.13 g obtained).
- iV-Methylmorpholine (0.12 mL) was added to reaction mixture. After 10 min, amine 10 (0.13 g, 0.41 mmol) in NMP (3 mL) was added. After 16 h, the reaction mixture was diluted with EtOAc and washed with dilute aqueous NaHCO 3 , IN HCl, water, and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The crude amide was purified by flash silica gel chromatography (3:2 hexane/EtOAc) to afford 0.20 g (92%, 2 steps) of 11 as a colorless oil.
- iV-Methylmorpholine (0.1 mL) was added to reaction mixture. After 10 min, amine 12 (0.14 g, 0.34 mmol) in NMP (3 mL) was added. After 72 h, the reaction mixture was diluted with EtOAc and washed with dilute aqueous NaHCO 3 , IN HCl, water, and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The crude amide was purified by flash silica gel chromatography (1:1 hexane/EtOAc) to afford 0.11 g (49%, 2 steps) of 13 as a colorless oil.
- [00175] A. 25-(3-Hydroxy-propyl)-4iS r -phenoxy-pyrrolidine-l-carboxylic acid tert- butyl ester (15): [Re: SRR-006-062] Palladium-on-carbon (10%, 0.3 g) was added to a solution of alcohol 8 (3 g, 9.4 mmol) in EtOAc (30 mL). The reaction mixture was placed on a Parr shaker and pressurized to 45 PSI H 2 (g). The heterogeneous mixture was shaken for 24 h at ambient temperature.
- the white precipitate was removed by filtration and washed with DCM.
- the clarified filtrate was washed successively with IM NaOH, water, and brine.
- the organic phase was dried with anhydrous Na 2 SO 4 , filtered, and concentrated.
- the crude ether was purified by flash silica gel chromatography (3 : 1 hexane/EtOAc) to afford 0.46 g of 16 as a colorless oil.
- Trifluoroacetic acid (2 mL) was added at ambient temperature to a solution of 16 (0.46 g, 1.08 mmol) in DCM (10 mL). After 1 h, the solution was concentrated to dryness and the crude product was dissolved in EtOAc. The organic solution was washed with aqueous NaHCO 3 , brine, dried over anhydrous Na 2 SO 4 , filtered, and concentrated to afford 0.30 g (85%) of 17 as a colorless oil.
- N-Methylmorpholine (0.05 mL) was added to reaction mixture. After 10 min, amine 19 (0.078 g, 0.18 mmol) in ⁇ MP (1 mL) was added. After 16 h, the reaction mixture was diluted with EtOAc and washed with dilute aqueous NaHCO 3 , IN HCl, water, and brine. The organic phase was dried over anhydrous Na 2 SO 4 , filtered and concentrated. The crude amide was purified by flash silica gel chromatography (1:1 hexane/EtOAc) to afford 0.038 g of 20 as a colorless oil.
- 2-methyl-propylcarbamoyl ⁇ -ethyl)-carbamic acid tert-butyl ester (31) A mixture of 30 (0.52 g, 0.90 mmol) and 10% Pd-on-carbon (0.05 g) in EtOAc (25 mL) was placed on a Parr apparatus and pressurized to 45 PSI H 2 atmosphere. The reaction mixture was shaken for 24 h. TLC analysis revealed only unconsumed starting material therefore the catalyst was removed by filtration and the clarified filtrate was concentrated to dryness. The residue was redissolved in EtOAc (25 mL) and 10% Pd-on-carbon (0.208 g) was added.
- the reaction mixture was shaken under a H 2 atmosphere (45 PSI) for 4 h at which time a second portion of palladium catalyst (0.05 g) was added. Hydrogenation was continued until all of the starting material was consumed ( ⁇ 2 h). The catalyst was removed by filtration and the filtrate was concentrated under reduced pressure. The crude product was purified by flash silica gel chromatography (EtOAc/hexane, 1:1) to afford 0.37 g (84%) of 31 as a white solid.
- reaction mixture was diluted with DCM and washed twice with 1 N NaOH, followed by brine, dried over anhydrous Na 2 SO 4 , filtered and concentrated.
- the crude product was purified by flash silica gel chromatography (EtOAc/hexane, 2:1) to afford 0.057 g (91%) of 33 as a white solid.
- reaction mixture was diluted with H 2 O, washed with saturated Na 2 S 2 O 8 , dried over Na 2 SO 4 , filtered, and concentrated. Purification of the residue by flash silica gel chromatography (3:1 hexane/EtOAc) afforded 1.1 g (61%) of 38 as a yellow oil.
- reaction mixture was diluted with diethyl ether and washed successively with NaHCO 3 , 1 M HCl, water, and brine.
- the organic extract was dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford 630 mg (96%) of 49 which was used without further purification.
- reaction mixture was diluted with diethyl ether and washed successively with NaHCO 3 , 1 M HCl, water, and brine.
- the organic extract was dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford 160 mg (quant.) of 51 which was used without further purification.
- reaction mixture was diluted with diethyl ether and washed successively with NaHCO 3 , 1 M HCl, water, and brine.
- the organic extract was dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford 3.0 g (87%) of 53 as an orange-colored oil which was used without further purification.
- D. Boc-protected Des-alanine Ornithine-derived Lactam (56) A solution containing 55 (2.3 g, 4.7 mmol) in 1:1 NMP/DCM (30 mL) was treated with HATU (2.1 g, 5.5 mmol) and NMM (0.6 mL, 5.5 mmol) at ambient temperature. After 18 h, the reaction mixture was diluted with diethyl ether and washed successively with aqueous Na 2 SO 4 , dilute aqueous HCl, water, brine, then dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford 1.5 g (68%) of 56 as an off-white-colored foam which was used without further purification.
- Boc-L-alanine (526 mg, 2.8 mmol) in NMP (5 mL) was treated with HATU (1.1 g, 2.9 mmol) followed by NMM (0.3 mL, 2.9 mmol) at ambient temperature. After 10 min, crude amine 57 (0.8 mg, 2.2 mmol) in NMP (10 mL) was added in a dropwise fashion. After 2 d, the reaction mixture was diluted with diethyl ether and washed successively with NaHCO 3 , 1 M HCl, water, and brine. The organic extract was dried over anhydrous Na 2 SO 4 , filtered and concentrated to afford ⁇ 1 g (84%) of 58 as a yellow-colored oil which was used without further purification. Mass spectrum: m/z 541 [M + H] + , and 563 [M + Na] + .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007521691A JP5230865B2 (en) | 2004-07-15 | 2005-07-15 | IAP binding compound |
EP05792764.2A EP1773766B1 (en) | 2004-07-15 | 2005-07-15 | Iap binding compounds |
AU2005274937A AU2005274937B2 (en) | 2004-07-15 | 2005-07-15 | IAP binding compounds |
ES05792764.2T ES2475207T3 (en) | 2004-07-15 | 2005-07-15 | IAP binding compounds |
CA2574040A CA2574040C (en) | 2004-07-15 | 2005-07-15 | Iap binding compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US58805004P | 2004-07-15 | 2004-07-15 | |
US60/588,050 | 2004-07-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006020060A2 true WO2006020060A2 (en) | 2006-02-23 |
WO2006020060A3 WO2006020060A3 (en) | 2007-02-15 |
Family
ID=35907930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2005/025208 WO2006020060A2 (en) | 2004-07-15 | 2005-07-15 | Iap binding compounds |
Country Status (7)
Country | Link |
---|---|
US (6) | US7456209B2 (en) |
EP (1) | EP1773766B1 (en) |
JP (1) | JP5230865B2 (en) |
AU (1) | AU2005274937B2 (en) |
CA (1) | CA2574040C (en) |
ES (1) | ES2475207T3 (en) |
WO (1) | WO2006020060A2 (en) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006091972A3 (en) * | 2005-02-25 | 2006-10-05 | Tetralogic Pharmaceuticals | Dimeric iap inhibitors |
US7244851B2 (en) | 2004-07-02 | 2007-07-17 | Genentech, Inc. | Inhibitors of IAP |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014252A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
WO2008014263A3 (en) * | 2006-07-24 | 2008-03-13 | Tetralogic Pharmaceuticals Cor | Dimeric iap antagonists |
US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
WO2008014240A3 (en) * | 2006-07-24 | 2008-10-16 | Tetralogic Pharmaceuticals Cor | Dimeric iap inhibitors |
US7456209B2 (en) | 2004-07-15 | 2008-11-25 | Tetralogic Pharmaceuticals Corporation | IAP binding compounds |
JP2009529544A (en) * | 2006-03-16 | 2009-08-20 | アエゲラ セラピューティクス インコーポレイテッド | Compounds that bind to the BIR domain of IAP |
JP2009537461A (en) * | 2006-05-16 | 2009-10-29 | アエゲラ セラピューティクス インコーポレイテッド | IAPBIR domain binding protein |
JP2010523717A (en) * | 2007-04-12 | 2010-07-15 | ジョイアント ファーマスーティカルズ、インク. | SMAC mimetic dimers and trimers useful as anticancer agents |
US8063095B2 (en) | 2005-10-25 | 2011-11-22 | Pharmascience Inc. | IAP BIR domain binding compounds |
US8063218B2 (en) | 2006-12-19 | 2011-11-22 | Genentech, Inc. | Imidazopyridine inhibitors of IAP |
US8247557B2 (en) | 2005-12-19 | 2012-08-21 | Genentech, Inc. | IAP inhibitors |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
US8445440B2 (en) | 2010-02-25 | 2013-05-21 | Novartis Ag | Dimeric IAP inhibitors |
US8575113B2 (en) | 2005-05-18 | 2013-11-05 | Pharmascience Inc. | BIR domain binding compounds |
US8609845B2 (en) | 2004-12-20 | 2013-12-17 | Genentech, Inc. | Pyrrolidine inhibitors of IAP |
WO2014074658A1 (en) * | 2012-11-09 | 2014-05-15 | Bristol-Myers Squibb Company | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
US8835393B2 (en) | 2008-08-02 | 2014-09-16 | Genentech, Inc. | Inhibitors of IAP |
US8907092B2 (en) | 2007-04-30 | 2014-12-09 | Genentech, Inc. | Inhibitors of IAP |
US8993523B2 (en) | 2010-12-13 | 2015-03-31 | Novartis Ag | Dimeric IAP inhibitors |
US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2022130411A1 (en) * | 2020-12-17 | 2022-06-23 | Council Of Scientific & Industrial Research | Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof |
EP3936126A4 (en) * | 2019-03-07 | 2022-12-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination of iap inhibitor and immune checkpoint inhibitor |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
CA2617642A1 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
BRPI0708942A2 (en) * | 2006-03-21 | 2011-06-14 | Joyant Pharmaceuticals Inc | apoptosis promoting compound, use and method of production thereof and pharmaceutical composition |
WO2008014238A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
CA2695384A1 (en) * | 2007-07-31 | 2009-02-05 | Burnham Institute For Medical Research | Bi-dentate compounds as kinase inhibitors |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
AU2009261919A1 (en) * | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
EP2478358A1 (en) | 2009-09-18 | 2012-07-25 | Novartis AG | Biomarkers for iap inhibitor compounds |
JP5529282B2 (en) | 2009-10-28 | 2014-06-25 | ジョイアント ファーマスーティカルズ、インク. | Dimeric Smac mimetics |
WO2011068926A1 (en) * | 2009-12-04 | 2011-06-09 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
DK2611797T3 (en) * | 2010-08-31 | 2017-02-13 | Hanmi Science Co Ltd | QUINOLINE OR QUINAZOLINE DERIVATIVES WITH APOPTOSE-INducing ACTIVITY ON CELLS |
EP2844764B1 (en) | 2012-05-04 | 2016-06-22 | Novartis AG | Biomarkers for iap inhibitor therapy |
CN103073473B (en) * | 2013-01-15 | 2017-06-23 | 天津药明康德新药开发有限公司 | The 2 pairs of hydroxyl pyrrolidine amino acid of luorobenzyl 3 and preparation method thereof and Anticancer Activities |
US9498532B2 (en) | 2013-03-13 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
US9498543B2 (en) | 2013-03-15 | 2016-11-22 | Novartis Ag | Antibody drug conjugates |
EP3151920A4 (en) | 2014-06-04 | 2017-12-27 | Sanford-Burnham Medical Research Institute | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy |
WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
BR112017001588A2 (en) | 2014-08-12 | 2017-11-21 | Novartis Ag | cdh6 antibody / drug conjugates |
US20190194315A1 (en) | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
MA44334A (en) | 2015-10-29 | 2018-09-05 | Novartis Ag | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST |
JOP20190187A1 (en) | 2017-02-03 | 2019-08-01 | Novartis Ag | Anti-ccr7 antibody drug conjugates |
WO2018163051A1 (en) | 2017-03-06 | 2018-09-13 | Novartis Ag | Methods of treatment of cancer with reduced ubb expression |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
AR111651A1 (en) | 2017-04-28 | 2019-08-07 | Novartis Ag | CONJUGATES OF ANTIBODIES THAT INCLUDE TOLL TYPE RECEIVER AGONISTS AND COMBINATION THERAPIES |
WO2018215937A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer |
EP3630162A1 (en) | 2017-05-24 | 2020-04-08 | Novartis AG | Antibody-cytokine engrafted proteins and methods of use |
AU2018274216A1 (en) | 2017-05-24 | 2019-12-12 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
FI3820573T3 (en) | 2018-07-10 | 2023-11-01 | Novartis Ag | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases |
AR116109A1 (en) | 2018-07-10 | 2021-03-31 | Novartis Ag | DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME |
WO2020089811A1 (en) | 2018-10-31 | 2020-05-07 | Novartis Ag | Dc-sign antibody drug conjugates |
CA3123511A1 (en) | 2018-12-20 | 2020-06-25 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CA3123996A1 (en) | 2018-12-21 | 2019-12-18 | Novartis Ag | Antibodies to pmel17 and conjugates thereof |
CA3123519A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
CN114514032A (en) | 2019-08-02 | 2022-05-17 | 兰提欧派普有限公司 | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer |
CN115175937A (en) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | Combination of anti-TIM-3 antibody MBG453 and anti-TGF-beta antibody NIS793 with or without decitabine or anti-PD-1 antibody, gabapentin, for the treatment of myelofibrosis and myelodysplastic syndrome |
US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
JP2023529211A (en) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | ZBTB32 inhibitors and uses thereof |
JP2023531676A (en) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | Dosing Regimens Containing 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione Derivatives |
WO2022029573A1 (en) | 2020-08-03 | 2022-02-10 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
EP4323526A1 (en) | 2021-04-16 | 2024-02-21 | Novartis AG | Antibody drug conjugates and methods for making thereof |
AR125874A1 (en) | 2021-05-18 | 2023-08-23 | Novartis Ag | COMBINATION THERAPIES |
WO2023214325A1 (en) | 2022-05-05 | 2023-11-09 | Novartis Ag | Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors |
WO2024023666A1 (en) | 2022-07-26 | 2024-02-01 | Novartis Ag | Crystalline forms of an akr1c3 dependent kars inhibitor |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3854480A (en) * | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
US3832253A (en) * | 1973-03-21 | 1974-08-27 | Baxter Laboratories Inc | Method of making an inflatable balloon catheter |
DE2714880A1 (en) * | 1977-04-02 | 1978-10-26 | Hoechst Ag | CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION |
US4667014A (en) * | 1983-03-07 | 1987-05-19 | Syntex (U.S.A.) Inc. | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists |
US4452775A (en) * | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
CA1200416A (en) * | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US5075109A (en) * | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5208007A (en) | 1988-11-22 | 1993-05-04 | Board Of Regents Of The University Of Oklahoma | Isotopic tracer composition and method for making and using same |
JPH04167172A (en) * | 1990-10-31 | 1992-06-15 | Nec Corp | Vector processor |
US5766572A (en) * | 1992-08-05 | 1998-06-16 | Meito Sangyo Kabushiki Kaisha | Water-soluble carboxypolysaccharide-magnetic iron oxide complex having a small particle diameter |
US6187557B1 (en) * | 1995-08-08 | 2001-02-13 | Tularik Inc. | c-IAP1 and c-IAP2: inhibitors of apoptosis |
US5786173A (en) * | 1996-03-19 | 1998-07-28 | Idun Pharmaceuticals, Inc. | MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use |
US6133437A (en) * | 1997-02-13 | 2000-10-17 | Apoptogen, Inc. | Modulation of IAPs for the treatment of proliferative diseases |
US5961955A (en) | 1997-06-03 | 1999-10-05 | Coulter Pharmaceutical, Inc. | Radioprotectant for peptides labeled with radioisotope |
US5977311A (en) | 1997-09-23 | 1999-11-02 | Curagen Corporation | 53BP2 complexes |
US6338811B2 (en) * | 1998-03-19 | 2002-01-15 | Seagate Technology | Surface planarization of magnetic disk media |
US6110691A (en) * | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
US6608026B1 (en) * | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
CA2420534A1 (en) | 2000-08-24 | 2002-02-28 | Thomas Jefferson University | An iap binding peptide or polypeptide and methods of using the same |
AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
US6992063B2 (en) * | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
US20020160975A1 (en) * | 2001-02-08 | 2002-10-31 | Thomas Jefferson University | Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis |
EP1421204A4 (en) * | 2001-05-31 | 2004-12-15 | Univ Princeton | Iap binding peptides and assays for identifying compounds that bind iap |
US7141589B2 (en) | 2001-08-23 | 2006-11-28 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of inhibiting formation of vascular channels and methods of inhibiting proliferation |
US20060258581A1 (en) * | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
JP2005510569A (en) * | 2001-11-21 | 2005-04-21 | ザ バーナム インスティチュート | Methods and compositions for activation of IAP-inhibited caspases |
WO2004005248A1 (en) | 2002-07-02 | 2004-01-15 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
ATE415413T1 (en) * | 2002-07-15 | 2008-12-15 | Univ Princeton | IAP BINDING COMPOUNDS |
US20080199439A1 (en) | 2003-02-12 | 2008-08-21 | Mclendon George L | IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
CA2553871A1 (en) | 2004-01-16 | 2005-08-04 | The Regents Of The University Of Michigan | Smac peptidomimetics and the uses thereof |
AU2005206929B2 (en) | 2004-01-16 | 2008-01-24 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
WO2005074989A2 (en) | 2004-02-05 | 2005-08-18 | Novartis Ag | Combination of a dna topoisomerase inhibitor and an iap inhibitor |
US20070217607A1 (en) | 2004-02-15 | 2007-09-20 | Matrixview Limited | Repetition Coded Compression For Encrypting Highly Correlated Data |
WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
EP1740173A4 (en) * | 2004-03-23 | 2009-05-27 | Genentech Inc | Azabicyclo-octane inhibitors of iap |
DK2253614T3 (en) | 2004-04-07 | 2013-01-07 | Novartis Ag | IAP inhibitors |
RU2401840C2 (en) * | 2004-07-02 | 2010-10-20 | Дженентек, Инк. | Iap inhibitors |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
WO2006017295A2 (en) | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Tetrapeptide analogs |
JP5230865B2 (en) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | IAP binding compound |
JP5007235B2 (en) * | 2004-12-20 | 2012-08-22 | ジェネンテック, インコーポレイテッド | IAP pyrrolidine inhibitors |
CN103083644B (en) * | 2005-02-25 | 2014-05-28 | 泰特拉洛吉克药业公司 | Dimeric iap inhibitors |
US20070003535A1 (en) * | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
US7772177B2 (en) * | 2005-05-18 | 2010-08-10 | Aegera Therapeutics, Inc. | BIR domain binding compounds |
WO2006128455A2 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
RU2007147959A (en) | 2005-06-08 | 2009-07-20 | Новартис АГ (CH) | ORGANIC COMPOUNDS |
CA2617642A1 (en) * | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
US20070203749A1 (en) | 2005-08-09 | 2007-08-30 | Sri Chunduru | Business methods for compounds for treatment of proliferative disorders |
CA2564872C (en) * | 2005-10-25 | 2010-12-21 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
WO2007106192A2 (en) | 2005-12-19 | 2007-09-20 | Genentech, Inc. | Inhibitors of iap |
JP5227805B2 (en) * | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Combination of IAP inhibitor and taxane 7 |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
TWI504597B (en) * | 2006-03-16 | 2015-10-21 | Pharmascience Inc | Iap bir domain binding compounds |
BRPI0708942A2 (en) * | 2006-03-21 | 2011-06-14 | Joyant Pharmaceuticals Inc | apoptosis promoting compound, use and method of production thereof and pharmaceutical composition |
PT2019671E (en) | 2006-05-05 | 2014-12-18 | Univ Michigan | Intermediates for the preparation of bivalent smac mimetics |
US8202902B2 (en) * | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
NZ572836A (en) * | 2006-05-16 | 2011-12-22 | Pharmascience Inc | Iap bir domain binding compounds |
WO2008014252A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
JP5228202B2 (en) | 2006-07-24 | 2013-07-03 | テトラロジック ファーマシューティカルズ コーポレーション | Dimeric IAP antagonist |
PE20110218A1 (en) | 2006-08-02 | 2011-04-01 | Novartis Ag | DERIVATIVES OF 2-OXO-ETHYL-AMINO-PROPIONAMIDE-PYRROLIDIN-2-IL-SUBSTITUTED AS INHIBITORS OF THE BINDING OF THE PROTEIN Smac TO THE INHIBITOR OF THE PROTEIN OF APOPTOSIS |
MX2009004061A (en) | 2006-10-19 | 2009-04-27 | Novartis Ag | Organic compounds. |
CA2671607A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Imidazopyridine inhibitors of iap |
CA2684169C (en) * | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
CL2008001234A1 (en) | 2007-04-30 | 2008-09-22 | Genentech Inc | COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF APOPTOSIS PROTEINS; AND USE IN THE TREATMENT OF CANCER. |
EP2328412A4 (en) | 2008-09-17 | 2012-03-14 | Tetralogic Pharm Corp | Iap inhibitors |
CA2763614A1 (en) | 2009-05-28 | 2010-12-02 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
WO2010138666A1 (en) | 2009-05-28 | 2010-12-02 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
-
2005
- 2005-07-15 JP JP2007521691A patent/JP5230865B2/en active Active
- 2005-07-15 CA CA2574040A patent/CA2574040C/en active Active
- 2005-07-15 AU AU2005274937A patent/AU2005274937B2/en active Active
- 2005-07-15 WO PCT/US2005/025208 patent/WO2006020060A2/en active Application Filing
- 2005-07-15 EP EP05792764.2A patent/EP1773766B1/en active Active
- 2005-07-15 US US11/184,503 patent/US7456209B2/en not_active Expired - Fee Related
- 2005-07-15 ES ES05792764.2T patent/ES2475207T3/en active Active
-
2008
- 2008-10-09 US US12/248,494 patent/US7968590B2/en not_active Expired - Fee Related
-
2011
- 2011-06-03 US US13/152,644 patent/US20110294827A1/en not_active Abandoned
-
2013
- 2013-06-25 US US13/926,283 patent/US8802716B2/en active Active
-
2014
- 2014-07-16 US US14/332,492 patent/US9394249B2/en active Active
-
2016
- 2016-06-15 US US15/182,921 patent/US9840464B2/en active Active
Non-Patent Citations (1)
Title |
---|
None |
Cited By (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
US7244851B2 (en) | 2004-07-02 | 2007-07-17 | Genentech, Inc. | Inhibitors of IAP |
US8110568B2 (en) | 2004-07-02 | 2012-02-07 | Genentech, Inc. | Inhibitors of IAP |
US8980837B2 (en) | 2004-07-02 | 2015-03-17 | Genentech, Inc. | Inhibitors of IAP |
US9840464B2 (en) | 2004-07-15 | 2017-12-12 | TetraLogic Birinapant UK Ltd. | IAP binding compounds |
US8802716B2 (en) | 2004-07-15 | 2014-08-12 | Tetralogic Pharmaceuticals Corporation | IAP binding compounds |
US7968590B2 (en) | 2004-07-15 | 2011-06-28 | Tetralogic Pharmaceuticals Corporation | IAP binding compounds |
US9394249B2 (en) | 2004-07-15 | 2016-07-19 | TetraLogic Birinapant UK Ltd. | IAP binding compounds |
US7456209B2 (en) | 2004-07-15 | 2008-11-25 | Tetralogic Pharmaceuticals Corporation | IAP binding compounds |
US9040706B2 (en) | 2004-12-20 | 2015-05-26 | Genentech, Inc. | Pyrrolidine inhibitors of IAP |
US8609845B2 (en) | 2004-12-20 | 2013-12-17 | Genentech, Inc. | Pyrrolidine inhibitors of IAP |
US9920093B2 (en) | 2005-02-25 | 2018-03-20 | TetraLogic Birinapant UK Ltd. | Dimeric IAP inhibitors |
AU2006216450B2 (en) * | 2005-02-25 | 2011-12-22 | Medivir Ab | Dimeric IAP inhibitors |
EA012810B1 (en) * | 2005-02-25 | 2009-12-30 | Тетралоджик Фармасеутикалс | Dimeric iap inhibitors |
WO2006091972A3 (en) * | 2005-02-25 | 2006-10-05 | Tetralogic Pharmaceuticals | Dimeric iap inhibitors |
US8822525B2 (en) | 2005-02-25 | 2014-09-02 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
KR101317661B1 (en) * | 2005-02-25 | 2013-10-15 | 테트랄로직 파마슈티칼스 코포레이션 | Dimeric IAP inhibitors |
US9187490B2 (en) | 2005-02-25 | 2015-11-17 | TetraLogic Birinapant UK Ltd. | Dimeric IAP inhibitors |
AU2006216450C1 (en) * | 2005-02-25 | 2013-01-10 | Medivir Ab | Dimeric IAP inhibitors |
US8022230B2 (en) | 2005-02-25 | 2011-09-20 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US8497297B2 (en) | 2005-02-25 | 2013-07-30 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
EP2385038A1 (en) * | 2005-02-25 | 2011-11-09 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US7517906B2 (en) | 2005-02-25 | 2009-04-14 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
US8575113B2 (en) | 2005-05-18 | 2013-11-05 | Pharmascience Inc. | BIR domain binding compounds |
US8063095B2 (en) | 2005-10-25 | 2011-11-22 | Pharmascience Inc. | IAP BIR domain binding compounds |
US8247557B2 (en) | 2005-12-19 | 2012-08-21 | Genentech, Inc. | IAP inhibitors |
JP2009529544A (en) * | 2006-03-16 | 2009-08-20 | アエゲラ セラピューティクス インコーポレイテッド | Compounds that bind to the BIR domain of IAP |
JP2009537461A (en) * | 2006-05-16 | 2009-10-29 | アエゲラ セラピューティクス インコーポレイテッド | IAPBIR domain binding protein |
WO2008014263A3 (en) * | 2006-07-24 | 2008-03-13 | Tetralogic Pharmaceuticals Cor | Dimeric iap antagonists |
WO2008014252A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
US7985735B2 (en) | 2006-07-24 | 2011-07-26 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP inhibitors |
AU2007276760B2 (en) * | 2006-07-24 | 2012-01-19 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP antagonists |
JP2009544727A (en) * | 2006-07-24 | 2009-12-17 | テトラロジック ファーマシューティカルズ コーポレーション | IAP inhibitor |
EP2409984A1 (en) * | 2006-07-24 | 2012-01-25 | Tetralogic Pharmaceuticals Corporation | Dimeric IAP Antagonists |
WO2008014240A3 (en) * | 2006-07-24 | 2008-10-16 | Tetralogic Pharmaceuticals Cor | Dimeric iap inhibitors |
US8143426B2 (en) | 2006-07-24 | 2012-03-27 | Tetralogic Pharmaceuticals Corporation | IAP inhibitors |
WO2008014252A3 (en) * | 2006-07-24 | 2008-03-13 | Tetralogic Pharmaceuticals Cor | Iap inhibitors |
WO2008014236A1 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US8063218B2 (en) | 2006-12-19 | 2011-11-22 | Genentech, Inc. | Imidazopyridine inhibitors of IAP |
JP2010523717A (en) * | 2007-04-12 | 2010-07-15 | ジョイアント ファーマスーティカルズ、インク. | SMAC mimetic dimers and trimers useful as anticancer agents |
US8907092B2 (en) | 2007-04-30 | 2014-12-09 | Genentech, Inc. | Inhibitors of IAP |
US8835393B2 (en) | 2008-08-02 | 2014-09-16 | Genentech, Inc. | Inhibitors of IAP |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
US11351221B2 (en) | 2009-07-02 | 2022-06-07 | Medivir Ab | SMAC mimetic |
US8986993B2 (en) | 2009-07-02 | 2015-03-24 | Tetralogic Pharmaceuticals Corporation | SMAC mimetic for treating myelodysplastic syndromes |
US8603816B2 (en) | 2009-07-02 | 2013-12-10 | Tetralogic Pharmaceuticals Corp. | SMAC mimetic |
US10034912B2 (en) | 2009-07-02 | 2018-07-31 | TetraLogic Birinapant UK Ltd. | SMAC Mimetic |
US10314881B2 (en) | 2009-07-02 | 2019-06-11 | Medivir Ab | SMAC mimetic |
US10596220B2 (en) | 2009-07-02 | 2020-03-24 | Medivir Ab | SMAC mimetic |
US11951147B2 (en) | 2009-07-02 | 2024-04-09 | Medivir Ab | SMAC mimetic |
US9284350B2 (en) | 2010-02-12 | 2016-03-15 | Pharmascience Inc. | IAP BIR domain binding compounds |
US8445440B2 (en) | 2010-02-25 | 2013-05-21 | Novartis Ag | Dimeric IAP inhibitors |
US8993523B2 (en) | 2010-12-13 | 2015-03-31 | Novartis Ag | Dimeric IAP inhibitors |
WO2014074658A1 (en) * | 2012-11-09 | 2014-05-15 | Bristol-Myers Squibb Company | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
EP3936126A4 (en) * | 2019-03-07 | 2022-12-21 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination of iap inhibitor and immune checkpoint inhibitor |
WO2021148396A1 (en) | 2020-01-20 | 2021-07-29 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
WO2022130411A1 (en) * | 2020-12-17 | 2022-06-23 | Council Of Scientific & Industrial Research | Smac mimetics for treatment of cancer, process for preparation and pharmaceutical composition thereof |
Also Published As
Publication number | Publication date |
---|---|
US7968590B2 (en) | 2011-06-28 |
US20060025347A1 (en) | 2006-02-02 |
AU2005274937B2 (en) | 2011-08-18 |
EP1773766B1 (en) | 2014-04-02 |
US20110294827A1 (en) | 2011-12-01 |
US20150307448A1 (en) | 2015-10-29 |
US20160289183A1 (en) | 2016-10-06 |
US7456209B2 (en) | 2008-11-25 |
WO2006020060A3 (en) | 2007-02-15 |
US20090048183A1 (en) | 2009-02-19 |
JP5230865B2 (en) | 2013-07-10 |
ES2475207T3 (en) | 2014-07-10 |
JP2008506712A (en) | 2008-03-06 |
EP1773766A2 (en) | 2007-04-18 |
US9394249B2 (en) | 2016-07-19 |
US20130289075A1 (en) | 2013-10-31 |
US9840464B2 (en) | 2017-12-12 |
CA2574040A1 (en) | 2006-02-23 |
US8802716B2 (en) | 2014-08-12 |
CA2574040C (en) | 2014-05-06 |
AU2005274937A1 (en) | 2006-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9840464B2 (en) | IAP binding compounds | |
US7718600B2 (en) | IAP binding compounds | |
Verdoes et al. | A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo | |
JP4954983B2 (en) | BIR domain binding compound | |
EP2024362A1 (en) | Iap bir domain binding compounds | |
WO2008144925A1 (en) | Iap bir domain binding compounds | |
US10383956B2 (en) | Fluorescent probe for detecting dipeptidyl peptidase IV | |
Dubowchik et al. | Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay | |
US20030125561A1 (en) | Uronium and immonium salts for peptide coupling | |
AU2002310004A1 (en) | Uronium and immonium salts for peptide coupling | |
CN110028508B (en) | Antitumor diazo bicyclic apoptosis protein inhibitor | |
MX2007000521A (en) | Iap binding compounds | |
US7482473B2 (en) | Coumarin derivative | |
Shi et al. | Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity | |
WO2023167282A1 (en) | O-function-type activatable raman probe | |
Berry et al. | Synthesis of external β-turn templates by reaction of protected dehydroamino acids with cyclic enaminoesters | |
US20110301233A1 (en) | Novel Polyisoprenylated Benzophenone Derivatives from Garcinia paucinervis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005274937 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007521691 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/000521 Country of ref document: MX Ref document number: 2574040 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005792764 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2005274937 Country of ref document: AU Date of ref document: 20050715 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005274937 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2005792764 Country of ref document: EP |